

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search

PubMed

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract

Show:

20

Sort

Send to

Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: J Exp Med 1996 Mar 1;183(3):867-78

Related Articles, Links


## Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines.

**Browning JL, Miatkowski K, Sizing I, Griffiths D, Zafari M, Benjamin CD, Meier W, Mackay F.**

Department of Immunology and Inflammation, Biogen, Cambridge, Massachusetts 02142, USA.

Surface lymphotoxin (LT) is a heteromeric complex of LT-alpha and LT-beta chains that binds to the LT-beta receptor (LT-beta-R), a member of the tumor necrosis factor (TNF) family of receptors. The biological function of this receptor-ligand system is poorly characterized. Since signaling through other members of this receptor family can induce cell death, e.g., the TNF and Fas receptors, it is important to determine if similar signaling events can be communicated via the LT-beta-R. A soluble form of the surface complex was produced by coexpression of LT-alpha and a converted form of LT-beta wherein the normally type II LT-beta membrane protein was changed to a type I secreted form. Recombinant LT-alpha 1/beta 2 was cytotoxic to the human adenocarcinoma cell lines HT-29, WiDr, MDA-MB-468, and HT-3 when added with the synergizing agent interferon (IFN) gamma. When immobilized on a plastic surface, anti-LT-beta-R monoclonal antibodies (mAbs) induced the death of these cells, demonstrating direct signaling via the LT-beta-R. Anti-LT-beta-R mAbs were also identified that inhibited ligand-induced cell death, whereas others were found to potentiate the activity of the ligand when added in solution. The human WiDr adenocarcinoma line forms solid tumors in immunocompromised mice, and treatment with an anti-LT-beta-R antibody combined with human IFN-gamma arrested tumor growth. The delineation of a biological signaling event mediated by the LT-beta-R opens a window for further studies on its immunological role, and furthermore, activation of the LT-beta-R may have an application in tumor therapy.

PMID: 8642291 [PubMed - indexed for MEDLINE]



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search PubMed

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract

Show:

20

Sort

Send to

Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: J Immunol 1989 Sep 15;143(6):1859-67

Related Articles, Links

## Studies on the differing effects of tumor necrosis factor and lymphotoxin on the growth of several human tumor lines.

**Browning J, Ribolini A.**

Department of Cell Biology and Immunology, Biogen Inc., Cambridge, MA 02142.

The relative ability of TNF and lymphotoxin (LT) to inhibit the growth of five human tumor cell lines was examined both in the presence and absence of IFN-gamma. Two adenocarcinoma lines, HT-29 and SK-CO-1, were 20- and 320-fold more sensitive to the inhibitory effects of TNF and LT in 3- to 4-day proliferation assays. In contrast, the breast carcinoma line BT-20 showed only a one- to twofold difference. The MCF-7 and ME-180 cell lines exhibited intermediate behavior. These results parallel the reported disparate potencies of TNF and LT in their effects on endothelial cells, hematopoietic development and their abilities to sustain a mixed lymphocyte response. Radiolabeled TNF binding studies showed two classes of receptors (Kd 0.04 to 0.15 nM and 0.2 to 1.0 nM) on the highly sensitive SK-CO-1 line. HT-29 cells also appeared to possess some high affinity-binding sites, whereas the BT-20 line completely lacked the high affinity form. Thus the presence of high affinity-binding sites correlated with increased sensitivity to the antiproliferative effects of TNF. Cold TNF competed with the binding of radiolabeled human TNF three- to fivefold better than LT for binding to all three lines. These relatively small differences between the TNF and LT receptor-binding characteristics are insufficient to explain the dramatic disparity in their antiproliferative properties. Likewise, the absolute concentrations of the unlabeled cytokines necessary to block the binding of 125I-TNF were 10- to 150-fold higher than the levels necessary to elicit the biologic response. Thus, the receptor binding data conflict with the growth inhibitory effects. This discrepancy is discussed in terms of either separate receptors for TNF and LT or more complex phenomena such as receptor cooperativity possibly resulting from multivalent interactions with the trimeric form of TNF.

PMID: 2550545 [PubMed - indexed for MEDLINE]

**WEST****End of Result Set**☐ **Generate Collection** **Print**

L1: Entry 1 of 1

File: USPT

Jul 20, 1999

US-PAT-NO: 5925351

DOCUMENT-IDENTIFIER: US 5925351 A

TITLE: Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

DATE-ISSUED: July 20, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Browning; Jeffrey L.	Brookline	MA		
Benjamin; Christopher D.	Beverly	MA		
Hochman; Paula S.	Brookline	MA		


US-CL-CURRENT: 424/143.1; 424/144.1, 424/145.1, 424/156.1, 514/2, 514/8, 530/387.1, 530/388.22, 530/388.23, 530/388.73, 530/388.85, 530/389.2, 530/395

## CLAIMS:

What is claimed is:

1. A method for altering a delayed type hypersensitivity response in an animal comprising the step of administering a pharmaceutical composition which comprises a therapeutically effective amount of a lymphotoxin -.beta. receptor blocking agent and a pharmaceutically acceptable carrier.
2. The method according to claim 1, wherein the lymphotoxin-.beta. receptor blocking agent is selected from the group consisting of a soluble lymphotoxin-.beta. receptor comprising a functional sequence of amino acids selected from the amino acids of SEQ.ID.NO.1, an antibody directed against lymphotoxin-.beta. receptor, and an antibody directed against a surface LT ligand comprising at least one lymphotoxin-.beta. subunit.
3. The method according to claim 2, wherein the animal is a mammal.
4. The method according to claim 3, wherein the mammal is a human.
5. The method according to claim 1, wherein the lymphotoxin-.beta.-receptor blocking agent comprises a soluble lymphotoxin-.beta. receptor comprising a functional sequence of amino acids selected from the amino acids of SEQ.ID.NO.1, and having a ligand binding domain that can bind to a surface LT ligand comprising at least one lymphotoxin-.beta. subunit.
6. The method according to claim 5, wherein the soluble lymphotoxin-.beta. receptor further comprises a human immunoglobulin Fc domain.
7. The method according to claim 1, wherein the LT-.beta.-R blocking agent comprises a monoclonal antibody directed against LT-.beta. receptor.
8. The method according to claim 7, wherein the composition is administered in an amount sufficient to coat LT-.beta. receptor-positive cells for 1 to 14 days.

9. The method according to claim 4, wherein the LT-.beta.-R blocking agent comprises anti-human LT-.beta.-R mAb BDA8 produced by the hybridoma cell line BD.A8.AB9 (ATCC Accession No: HB11798).
10. The method according to claim 1, wherein the LT-.beta.-R blocking agent comprises a monoclonal antibody directed against surface LT ligand.
11. The method according to claim 10, wherein the composition is administered in an amount sufficient to coat surface LT ligand-positive cells for 1 to 14 days.
12. The method according to claim 10, wherein the antibody is directed against a subunit of the LT ligand.
13. The method according to claim 4, wherein the LT-.beta.-R blocking agent comprises anti-human LT-.beta. mAb B9 produced by the hybridoma cell line B9.C9.1 (ATCC Accession No: 11962).
14. The method according to claim 3, wherein the mammal is a mouse and the LT-.beta.-R blocking agent comprises a monoclonal antibody directed against a murine surface LT ligand.
15. A method for treating inflammatory bowel disease in an animal comprising the step of administering a pharmaceutical composition which comprises a therapeutically effective amount of a lymphotoxin-.beta. receptor blocking agent and a pharmaceutically acceptable carrier.
16. The method according to claim 15 wherein the lymphotoxin-.beta. receptor blocking agent is selected from the group consisting of a soluble lymphotoxin-.beta. receptor comprising a functional sequence of amino acids selected from the amino acids of SEQ. ID.NO.1, an antibody directed against lymphotoxin .beta. receptor, and an antibody directed against a surface LT ligand comprising at least one lymphotoxin-.beta. subunit.



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search PubMed



for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract



Show:

20



Sort



Send to

Text



Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: J Immunol 1995 Jan 1;154(1):33-46

Related Articles, Links

## Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.

**Browning JL, Douglas I, Ngam-ek A, Bourdon PR, Ehrenfels BN, Miatkowski K, Zafari M, Yampaglia AM, Lawton P, Meier W, et al.**

Department of Immunology and Inflammation, Biogen, Cambridge, MA 02142.

Lymphotoxin (LT) is a cytokine related to TNF, found in human systems in both secreted and membrane bound forms. The well characterized secreted form is a trimer of a single protein, LT-alpha, whereas the surface form is composed of a complex between two related molecules, LT-alpha and LT-beta. Because there is a distinct receptor for the complex, the membrane form is believed to signal via events different from those elicited by TNF and secreted LT-alpha. By using a battery of anti-LT-alpha and LT-beta mAbs, it is clear that two LT surface forms exist on the surface of PMA-activated II-23 cells, a human T cell hybridoma. Assuming that these surface forms are trimers, a minor form appears early after induction having an apparent stoichiometry of LT-alpha 2/beta 1 and is recognized by one group of anti-LT-alpha mAbs and the p55-TNF receptor. The second and predominant form has an apparent LT-alpha 1/beta 2 composition and is recognized by a second group of pan-tropic anti-LT-alpha mAbs and the LT-beta receptor. Neither of the heteromeric forms nor a putative LT-beta homotrimeric form were found to be secreted. The properties of surface LT on the II-23 cell system were similar to those of the surface LT forms on Chinese hamster ovary cells transfected with both LT-alpha and LT-beta genes and a number of lymphoid tumor lines. These experiments point toward the LT-alpha 1/beta 2 complex as the predominant membrane form of LT on the lymphocyte surface, and this complex is the primary ligand for the LT-beta receptor.

PMID: 7995952 [PubMed - indexed for MEDLINE]

Display

Abstract



Show:

20




Sort



Send to

Text





PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search

PubMed



for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract



Show:

20



Sort



Send to

Text



Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: J Immunol 1997 Oct 1;159(7):3299-310[Related Articles, Links](#)


## Cytotoxic activities of recombinant soluble murine lymphotoxin-alpha and lymphotoxin-alpha beta complexes.

Mackay F, Bourdon PR, Griffiths DA, Lawton P, Zafari M, Sizing ID, Miatkowski K, Ngam-ek A, Benjamin CD, Hession C, Ambrose CM, Meier W, Browning JL.

Department of Immunology, Biogen, Cambridge, MA 02142, USA.

Human lymphotoxin-alpha (LT alpha) is found in a secreted form and on the surface of lymphocytes as a complex with a second related protein called lymphotoxin-beta (LT beta). Both secreted human LT alpha and TNF have similar biological activities mediated via the TNF receptors, whereas the cell surface LT alpha beta complex binds to a separate receptor called the LT beta receptor (LT beta R). The murine LT alpha and LT beta (mLT alpha and mLT beta) proteins have never been characterized. When recombinant mLT alpha was produced by either of several methods, the protein had a very low specific activity relative to that of human LT alpha in the conventional WEHI 164 cytotoxicity bioassay. The weak activity observed was inhibited by a soluble murine TNF-R55 Ig fusion protein (mTNF-R55-Ig), but not by mLT beta R-Ig. Coexpression of both mLT alpha and a soluble version of mLT beta in insect cells led to an LT alpha beta form that was cytotoxic in the WEHI 164 assay via the LT beta R. To determine whether natural mLT alpha-like forms with cytotoxic activity comparable to that of secreted human LT alpha were secreted from primary spleen cells, splenic lymphocytes were activated in various ways, and their supernatants were analyzed for cytotoxic activity. Using specific Abs to distinguish between mTNF and mLT, a TNF component was readily detected; however, there was no evidence for a secreted mLT alpha cytotoxic activity using this assay. Combined, these observations suggest that secreted mLT alpha may not play a role in the mouse via interactions with TNF-R55, and the ramifications of this hypothesis are discussed.

PMID: 9317128 [PubMed - indexed for MEDLINE]



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search PubMed



for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract

Show:

20

Sort

Send to

Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: J Immunol 1997 Oct 1;159(7):3288-98

Related Articles, Links

## Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes.

**Browning JL, Sizing ID, Lawton P, Bourdon PR, Rennert PD, Majeau GR, Ambrose CM, Hession C, Miatkowski K, Griffiths DA, Ngam-ek A, Meier W, Benjamin CD, Hochman PS.**

Department of Immunology, Biogen, Cambridge, MA 02142, USA.  
Jeff\_Browning@biogen.com

The lymphotoxin-alpha beta complex (LT alpha beta) is found on the surface of activated lymphocytes and binds to a specific receptor called the LT beta receptor (LT beta R). In the mouse, signaling through this pathway is important for lymph node development and splenic organization, yet the biochemical properties of murine LT alpha and LT beta are essentially unknown. Here we have used soluble receptor-Ig forms of LT beta R and TNF-R55 and mAbs specific for murine LT alpha, LT beta, and LT beta R to characterize the appearance of surface LT alpha beta complexes and LT beta R on several common murine cell lines. Cells that bound LT beta R also bound anti-LT alpha and anti-LT beta mAbs in a FACS analysis. The ability of these reagents to discriminate between surface TNF and LT was verified by analysis of surface TNF-positive, LPS-activated murine RAW 264.7 monocytic cells. Primary mouse leukocytes from spleen, thymus, lymph node, and peritoneum were activated in vitro, and CD4+ and CD8+ T cells as well as B cells expressed surface LT ligand but not the LT beta R. Conversely, elicited peritoneal monocytes/macrophages were surface LT negative yet LT beta R positive. This study shows that on mononuclear cells, surface LT complexes and receptor are expressed similarly in mice and man, and the tools described herein form the foundation for study of the functional roles of the LT system in the mouse.

PMID: 9317127 [PubMed - indexed for MEDLINE]

Display

Abstract

Show:

20

Sort

Send to

Text

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
[Department of Health & Human Services](#)  
[Freedom of Information Act](#) | [Disclaimer](#)

i686-pc-linux-gnu Feb 4 2003 11:11:49



Display	Abstract	Show: 20	Sort	Send to	Text
---------	----------	----------	------	---------	------

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
[Department of Health & Human Services](#)  
[Freedom of Information Act](#) | [Disclaimer](#)

i686-pc-linux-gnu Feb 4 2003 11:11:49

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sespral642cxy

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 BELSTEIN: Reload and implementation of a New Subject Area  
NEWS 4 ZDB will be removed from STN  
NEWS 5 Apr 09 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 6 Apr 22 Records from IP.COM available in CAPUS, HCAPUS, and ZCAPUS  
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03 New e-mail delivery for search results now available  
NEWS 10 MEDLINE Reload  
NEWS 11 PCTFUL has been reloaded  
NEWS 12 FORESE no longer contains STANDARDS file segment  
NEWS 13 USAN to be reloaded July 28, 2002;  
NEWS 14 saved answer sets no longer valid  
NEWS 15 Jul 29 Enhanced polymer searching in REGISTRY  
NEWS 16 Jul 30 NETFIRST to be removed from STN  
NEWS 17 Aug 08 CANCERLIT reload  
NEWS 18 Aug 08 PHARMAMarketLetter (PHARMAM) - new on STN  
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03 JAPLO has been reloaded and enhanced  
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 25 Sep 16 CA Section Thesaurus available in CAPUS and CA  
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 27 Oct 21 EVENTLINE has been reloaded  
NEWS 28 Oct 24 BELSTEIN adds new search fields  
NEWS 29 Oct 24 Nutraceuticals International (NUTRACUT) now available on STN  
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002  
NEWS 31 Nov 18 DKILIT has been renamed APOULIT  
NEWS 32 Nov 25 More calculated properties added to REGISTRY  
NEWS 33 Dec 02 TIBKAT will be removed from STN  
NEWS 34 Dec 04 CSA files on STN  
NEWS 35 Dec 17 PCTFUL now covers WP/PCT Applications from 1978 to date  
NEWS 36 Dec 17 TOXCENTER enhanced with additional content  
NEWS 37 Dec 17 Adis Clinical Trials insight now available on STN  
NEWS 38 Dec 30 ISMEC no longer available  
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPUS  
NEWS 40 Jan 21 NUTRACUT offering one free connect hour in February 2003  
NEWS 41 Jan 21 PHARMAM offering one free connect hour in February 2003  
NEWS 42 Jan 23 Simultaneous left and right truncation added to COMPENDEX,  
ENERGY, INSPEC  
NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,  
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 12:32:53 ON 11 FEB 2003

=> file medline, cancerlit, biosis, confsci, embase, caplus, uspatfull  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 12:33:20 ON 11 FEB 2003

FILE 'CANCERLIT' ENTERED AT 12:33:20 ON 11 FEB 2003

FILE 'BIOSIS' ENTERED AT 12:33:20 ON 11 FEB 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CONFSCI' ENTERED AT 12:33:20 ON 11 FEB 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'EMBASE' ENTERED AT 12:33:20 ON 11 FEB 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 12:33:20 ON 11 FEB 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:33:20 ON 11 FEB 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 'lymphotoxin (a) beta (a) receptor and antibody?

5 FILES SEARCHED...

136 LYMPHOTOXIN (A) BETA (A) RECEPTOR AND ANTIBODY?

=> s '11 and interferon?

42 11 AND INTERFERON?

=> dup rem 12

PROCESSING COMPLETED FOR L2

L3 34 DUP REM L2 (8 DUPLICATES REMOVED)

=> d 1-34

L3 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1

AN 2002:409195 CAPLUS

DN 137:1567

TI Human apoptosis inducing molecule II and its cDNA and use thereof in drug

PCT Int. Appl., 41 pp  
CODEN: PIXXD2

IC [7]  
 ICM: C12P021-02  
 ICS: C12N005-06; C07H021-04; C12N009-12  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 34 USPATFULL  
 AN 2002:272468 USPATFULL  
 TI Tumor necrosis factor receptors 6alpha & 6beta  
 IN Gentz, Reinhard, Galtersburg, MD, UNITED STATES  
 PI US 2001-768779 AI 20010125 (9)  
 AI US 2001-768779 AI 20010125 (9)  
 PRAI US 1997-48020P 19970529 (60)  
 DT Utility  
 FS APPLICATION  
 INCL INCLM: 435/069.100  
 INCL INCLM: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
 NCL INCLM: 435/069.100  
 NCLM: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
 IC [7]  
 ICM: C07K014-715  
 ICS: C12P021-02; C12N005-06; C07H021-04  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. Corporation)  
 PI US 2002:50583 AI 20021017  
 AI US 2001-935727 AI 20010824 (9)  
 RLI PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING

PRAI US 2001-303224P 20010706 (60)  
 US 2000-252131P 20001121 (60)  
 US 2000-227598P 20000825 (60)  
 US 1999-168235P 19991201 (60)  
 US 1999-146371P 19990802 (60)  
 US 1999-131964P 19990430 (60)  
 US 1999-131270P 19990427 (60)  
 US 1999-124092P 19990312 (60)  
 RLI US 1999-121774P 19990304 (60)  
 US 1997-35496P 19970114 (60)  
 DT Utility  
 FS APPLICATION

INCL INCLM: 424/178.100  
 INCL INCLM: 530/388.100  
 NCL INCLM: 424/178.100  
 NCLM: 530/388.100  
 IC [7]  
 ICM: A61K039-395  
 ICS: C07K016-46  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 34 USPATFULL  
 AN 2002:259408 USPATFULL  
 TI Gene expression profiles in liver cancer  
 IN Horne, Darci T., Galtersburg, MD, UNITED STATES  
 PI US 2002:142981 AI 20021003  
 AI US 2001-880107 AI 20010614 (9)  
 PRAI US 2000-211379P 20000614 (60)  
 DT Utility  
 FS APPLICATION

INCL INCLM: 514/044.000  
 INCL INCLM: 435/006.000  
 NCL INCLM: 514/044.000  
 NCLM: 435/006.000  
 IC [7]  
 ICM: A61K048-00  
 ICS: C12N001-68  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 34 USPATFULL  
 AN 2002:235448 USPATFULL  
 TI Human tumor necrosis factor receptor-like protein 8  
 IN Ni, Jian, Rockville, MD, UNITED STATES  
 PI US 2002:127637 AI 20020912  
 AI US 2001-768779 AI 20010125 (9)  
 PRAI US 1997-48020P 19970529 (60)  
 DT Utility  
 FS APPLICATION

INCL INCLM: 435/069.100  
 INCL INCLM: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
 NCL INCLM: 435/069.100  
 NCLM: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
 IC [7]  
 ICM: C07K014-715  
 ICS: C12P021-02; C12N005-06; C07H021-04  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 34 USPATFULL  
 AN 2002:235425 USPATFULL  
 TI TRAF-3 deletion isoforms and uses thereof  
 IN Lederman, Seth, New York, NY, UNITED STATES  
 PI US 2002:127615 AI 20020912  
 AI US 2001-950902 AI 20010910 (9)  
 RLI Continuation of Ser. No. WO 2000-056503, filed on 10 Mar 2000, UNKNOWN  
 PENDING Continuation-in-part of Ser. No. US 1999-268544, filed on 11 Mar 1999,  
 DT Utility  
 FS APPLICATION

INCL INCLM: 435/007.210  
 INCL INCLM: 435/183.000; 435/325.000; 435/320.100; 530/350.000; 536/023.200  
 NCL INCLM: 435/007.210  
 NCLM: 435/183.000; 435/325.000; 435/320.100; 530/350.000; 536/023.200  
 IC [7]  
 ICM: G01N033-567  
 ICS: C07H021-04; C12N009-00; C07K014-705  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 34 USPATFULL  
 AN 2002:206139 USPATFULL  
 TI Compositions and methods for the therapy and diagnosis of colon cancer  
 IN Xu, Jiangchun, Bellevue, WA, UNITED STATES  
 PI US 2002:110832 AI 20020815  
 AI US 2001-919580 AI 20010730 (9)  
 PRAI US 2001-302702P 20010730 (60)  
 DT Utility  
 FS APPLICATION

INCL INCLM: 435/007.100  
 INCL INCLM: 536/023.100; 530/350.000  
 NCL INCLM: 435/007.100  
 NCLM: 536/023.100; 530/350.000  
 IC [7]  
 ICM: G01N033-567  
 ICS: C07H021-04; C12N009-00; C07K014-705  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ICM: G01N033-53  
ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 34 USPATFULL  
AN 2002:171619 USPATFULL  
TI Anti-lymphotoxin-beta receptor  
IN Antibodies as anti-tumor agents  
Browning, Jeffrey L., Brookline, MA, UNITED STATES  
Meier, Werner, Burlington, MA, UNITED STATES  
Benjamin, Christopher D., Beverly, MA, UNITED STATES  
PI US 2002090366 A1 20020711  
AI US 2001-933402 A1 20010816 (9)  
R1 Division of Ser. No. US 1998-875560, filed on 5 Jun 1998, PATENTED A 371  
of International Ser. No. WO 1996-US1386, filed on 26 Jan 1996, UNKNOWN  
Continuation-in-part of Ser. No. US 1995-378968, filed on 26 Jan 1995.  
PENDING

DT Utility  
FS APPLICATION  
IN.CNT 1764  
INCL INCLM: 424/094.100  
NCL INCLM: 424/178.100  
NCLM: 424/094.100  
IC NCLS: 424/178.100  
[7]  
ICM: A61K039-395  
ICS: A61K039-40

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 34 USPATFULL  
AN 2002:157048 USPATFULL  
TI APOPTOSIS INDUCING MOLECULE 11 AND METHODS OF USE  
EBNER, REINHARD, GAITHERSBURG, MD, UNITED STATES  
YU, GUO-LIANG, BERKELEY, CA, UNITED STATES  
RUBEN, STEVEN M., Olney, MD, UNITED STATES  
ZHANG, JUN, BETHESDA, MD, UNITED STATES  
ULRICH, STEPHEN, ROCKVILLE, MD, UNITED STATES  
ZHA, YIPAN, GAITHERSBURG, MD, UNITED STATES  
PA Human Genome Sciences (U.S. corporation)  
PI US 2002081647 A1 20020627  
B2 20021217  
AI US 1999-252656 A1 19990219 (9)  
R1 Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998,  
PENDING Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan  
1998, ABANDONED Continuation-in-part of Ser. No. US 1997-822953, filed  
on 21 Mar 1997, ABANDONED  
PRAI US 1998-75409P 19980220 (60)  
US 1996-13923P 19960322 (60)  
US 1996-30157P 19961031 (60)

DT Utility  
FS APPLICATION  
IN.CNT 6195  
INCL INCLM: 435/069.100  
NCL INCLM: 530/350.000; 530/399.000; 514/012.000; 536/023.500  
NCLM: 514/012.000  
IC NCLS: 530/300.000; 530/324.000; 530/350.000  
[7]  
ICM: A61K038-18  
ICS: C12P021-06; C07H021-04; C07K014-00; G01N033-53  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 34 USPATFULL  
AN 2002:119846 USPATFULL  
TI Human G-protein Chemokine receptor (CCRS) HDGNR10  
IN Rosen, Craig A., Laytonville, MD, UNITED STATES

Roschke, Viktor, Rockville, MD, UNITED STATES  
Li, Yi, Sunnyvale, CA, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
PI US 2002061834 A1 20020523  
AI US 2001-779880 A1 20010209 (9)  
PRAI US 2000-18128P 20000209 (60)  
US 2000-187999P 20000309 (60)  
US 2000-234336P 20000922 (60)

DT Utility  
FS APPLICATION  
IN.CNT 18667  
INCL INCLM: 514/001.000  
NCL INCLM: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100  
NCLM: 514/001.000  
IC NCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100  
[7]  
ICM: A61K031-00  
ICS: C07H021-04; C07K014-705; C12N005-06; C12P021-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 34 USPATFULL  
AN 2002:92268 USPATFULL  
TI Human G-protein Chemokine Receptor HDGNR10  
IN Rosen, Craig A., Laytonville, MD, UNITED STATES  
Roschke, Viktor, Rockville, MD, UNITED STATES  
Li, Yi, Sunnyvale, CA, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
PI US 2002048786 A1 20020425  
AI US 2001-779879 A1 20010209 (9)  
PRAI US 2000-181258P 20000209 (60)  
US 2000-187999P 20000309 (60)  
US 2000-234336P 20000922 (60)

DT Utility  
FS APPLICATION  
IN.CNT 17969  
INCL INCLM: 435/069.100  
NCL INCLM: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000  
NCLM: 435/069.100  
IC NCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000  
[7]  
ICM: G01N033-53  
ICS: G01N033-567; A61K038-00; C07H021-04; C12P021-06; A61K039-395;  
C12N005-02; C12N005-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 34 USPATFULL  
AN 2002:67215 USPATFULL  
TI Method for detecting hepatitis C  
IN Budkowska, Agata, Clamart, FRANCE  
Mailard, Patrick, Montlhery, FRANCE  
Bromert, Christian, Fresnes, FRANCE  
Gounon, Pierre, Noisieu, FRANCE  
Nikiewicz, Jadwiga, Komorow, POLAND  
Grainic, Radu, Joux En Josas, FRANCE  
PA INSTITUT PASTEUR, Paris Cedex, FRANCE, 75724 (non-U.S. corporation)  
PI US 2002037868 A1 20020328  
AI US 2001-880945 A1 20010615 (9)  
R1 Continuation-in-part of Ser. No. US 2000-549685, filed on 14 Apr 2000,  
PENDING  
PRAI US 1999-129319P 19990414 (60)

DT Utility  
FS APPLICATION  
IN.CNT 1656  
INCL INCLM: 514/044.000  
INCLM: 435/005.000; 435/007.950; 435/091.330; 435/975.000

NCL NCLM: 514/044.000  
NCLS: 435/005.000; 435/007.950; 435/091.330; 435/975.000  
IC [7]

ICM: C120001-70  
ICS: G01N033-53; G01N033-537; G01N033-543; A61K031-70; A01N043-04;  
C12P019-34

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 34 USPTAFULL  
TI Antagonists of tweak and of tweak receptor and their use to treat immunological disorders  
IN Remmert, Paul, Miller, MA, UNITED STATES  
PI US 2002015703 A1 20020207  
AI US 2001-905810 A1 20010713 (9)  
PRAI WO 2000-US1044 20000114  
DT US 1999-116168P 19990115 (60)  
FS APPLICATION  
LN.CNT 1303  
INCL INCLM: 424/143.100  
NCL NCLM: 424/143.100  
IC [7]

ICM: A61K039-395  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 34 USPTAFULL  
TI Nucleic acid sequences associated with aging, particularly skin aging  
IN Burnet, Glenn C., Seattle, WA, UNITED STATES  
PI US 2002012927 A1 20020131  
AI US 2001-802718 A1 20010308 (9)  
PRAI US 2000-188584P 20000310 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2368  
INCL INCLM: 435/006.000  
NCL NCLS: 435/007.210  
NCLM: 435/006.000  
NCLS: 435/007.210  
IC [7]

ICM: C120001-68  
ICS: G01N033-567; A61K031-665  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 17 OF 34 USPTAFULL  
TI Multivalent antibodies and uses therefor  
IN Miller, Kathy L., San Francisco, CA, UNITED STATES  
PI Prester, Leonard G., San Francisco, CA, UNITED STATES  
GENENTECH, INC. (U.S. corporation)  
PI US 2002004587 A1 20020110  
AI US 2001-813341 A1 20010320 (9)  
PRAI US 2000-195819P 20000411 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4913  
INCL INCLM: 530/388.800  
NCL NCLS: 536/023.500; 435/325.000; 435/334.000; 424/143.100  
NCLM: 530/388.800  
NCLS: 536/023.500; 435/325.000; 435/334.000; 424/143.100  
IC [7]

ICM: C07K016-28

ICS: A61K039-395; C07H021-04; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 18 OF 34 USPTAFULL  
TI Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway  
IN Browning, Jeffrey, Brookline, MA, UNITED STATES  
PI Pugliese, Maryann, Alexandria, VA, UNITED STATES  
PI US 2002001585 A1 20020103  
AI US 2001-829031 A1 20010409 (9)  
PRAI US 1998-103662P 19981009 (60)  
DT Continuation of Ser. No. WO 1999-US23477, filed on 8 Oct 1999, UNKNOWN  
FS Utility  
LN.CNT 1040  
INCL INCLM: 424/143.100  
NCL NCLS: 424/147.100; 435/328.000; 435/334.000  
NCLM: 424/143.100  
NCLS: 424/147.100; 435/328.000; 435/334.000  
IC [7]

ICM: A61K039-42  
ICS: A61K039-395; C12N005-06; C12N005-16  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 19 OF 34 USPTAFULL  
TI Nucleic acid encoding a TRAF-3 deletion isoform  
IN Lederman, Seth, New York, NY, United States  
PI Van Eynhoven, Wintfried, Bayside, NY, United States  
The Trustees of the University in the City of New York, New York, NY, United States (U.S. corporation)  
PI US 6410710 B1 20020625  
AI US 1999-268544 19990311 (9)  
DT Utility  
FS GRANTED

LN.CNT 3011  
INCL INCLM: 536/023.500  
NCL NCLS: 536/023.100; 435/320.100  
NCLM: 536/023.500  
NCLS: 435/320.100; 536/023.100  
IC [7]

ICM: C07H021-04  
ICS: C12N015-11; C12N015-63  
EXF 536/23.1; 536/23.5; 435/320.1; 424/93.1; 514/44  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 20 OF 34 USPTAFULL  
TI Soluble lymphotoxin-beta receptors as therapeutic agents for the treatment of immunological disease  
IN Browning, Jeffrey L., Brookline, MA, United States  
PI Benjamin, Christopher D., Beverly, MA, United States  
Hochman, Paula S., Newton, MA, United States  
Biosgen, Inc., Cambridge, MA, United States (U.S. corporation)  
PI US 6403087 B1 20020611  
AI WO 9703687 19970206  
WO 1998-166 19980608 (9)  
US 1998-166 19960719  
WO 1996-US12010 19980608 PCT 371 date  
Continuation-in-part of Ser. No. US 1995-505606, filed on 21 Jul 1995,  
now patented, Pat. No. US 5925351  
DT Utility  
FS GRANTED

LN CNT 1983  
INCL INCLM: 424/134.100  
INCLM: 424/134.100; 424/133.100; 514/002.000; 514/008.000; 530/387.100;  
530/387.300  
NCLM: 424/134.100  
NCLM: 424/133.100; 514/002.000; 514/008.000; 530/387.100; 530/387.300  
IC [7]  
ICM: A61K039-395  
EXF 424/148.1; 424/144.1; 424/145.1; 424/156.1; 514/2; 514/8; 530/395;  
530/387.1; 530/388.22; 530/388.73; 530/388.85; 530/389.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L3 ANSWER 21 OF 34 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 2002:419176 BIOSIS  
DN PREV200200419176  
TI Lymphotoxin-beta receptor agonist monoclonal  
AU antibodies have antitumor properties.  
Lepage, Doreen J. (1); Wilson, C. A.; Garber, E.; Bailey, V.; Ngam-Ek, A.;  
Dirig, J.; Jarpe, M.; Lukashew, M.; Xu, X.; Szelliga, K.; Kelly, R.; Fawell,  
S.; Tao, N.; Boral, A.; Myers, J.; Browning, J.  
CS (1) Biogen, Inc., Cambridge, MA USA  
SO Proceedings of the American Association for Cancer Research Annual  
Meeting, (March, 2002) Vol. 43, pp. 1005. Print.  
Meeting Info.: 93rd Annual Meeting of the American Association for Cancer  
Research San Francisco, California, USA April 06-10, 2002  
ISSN: 0197-016X.  
DT Conference  
LA English  
L3 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2003 ACS  
AN 2001:904598 CAPLUS  
DN 136:2535  
TI Compositions, kits, and methods for identification and modulation of type  
I diabetes  
IN Byrne, Michael C.; Hill, Andrew A.; Wilson, S. Brian  
PA Genetics Institute, Inc., USA; General Hospital Corporation  
SO PCT Int. Appl., 123 pp.  
CODEN: PIXD2  
DT Patent  
LA English  
FAN.CNT 1  
PATENT NO. KIND DATE APPLICATION NO. DATE  
PI WO 2001094636 A2 20011213 WO 2001-US18418 20010605  
W: AE, AG, AU, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MC, MK, MN, MM, MY, NA, NZ, NL, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,  
VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, BY, BZ, CA, CH, CN, CY, CZ, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
RW: GM, KE, KE, KE, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
PRAI US 2002039736 A1 20020404 US 2001-875451 20010605  
PRAI US 2000-209703P P 20000605  
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

PA National Science Council, Taiwan  
SO Taiwan, 5 pp.  
CODEN: TWXMA5  
DT Patent  
LA Chinese  
FAN.CNT 1  
PATENT NO. KIND DATE APPLICATION NO. DATE  
PI TW 434316 B 20010516  
PRAI TW 1998-87113614 19980819  
L3 ANSWER 24 OF 34 USPTFULL  
AN 2001:231143 USPTFULL  
TI Arrays for identifying agents which mimic or inhibit the activity of  
interferons  
IN Silverman, Robert H.; Beachwood, OH, United States  
Williams, Bryan R. G., Cleveland, OH, United States  
Der, Sandy, Cleveland, OH, United States  
The Cleveland Clinic Foundation, Cleveland, OH, United States (U.S.  
corporation)  
PI US 6311396 B1 20011218  
AI US 1999-405438 19990923 (9)  
PRAI US 1998-101497P 19980923 (60)  
DT Utility  
FS GRANTED  
LN.CNT 9639  
INCL INCLM: 435/006.000  
INCLM: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310  
NCLM: 435/006.000  
NCLM: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310  
IC [7]  
ICM: C120001-68  
EXF ICS: C12M001-36; C07H021-04  
435/6; 435/287.2; 536/23.1; 536/24.31; 536/23.52  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L3 ANSWER 25 OF 34 USPTFULL  
AN 2001:196600 USPTFULL  
TI Lymphotoxin-.alpha.-.beta. complexes and anti-lymphotoxin-.beta. receptor  
antibodies as anti-tumor agents  
IN Browning, Jeffrey L., 32 Milton Rd., Brookline, MA, United States 02146  
Meier, Werner, 31 Bedford St., Burlington, MA, United States 01803  
Benjamin, Christopher D., 2 Oak Hill La., Beverly, MA, United States  
01915  
PI US 6312691 B1 20011106  
AI WO 9622788 19960801  
US 1998-875560 19980605 (8)  
WO 1996-US1386 19960126  
19980605 PCT 371 date  
19980605 PCT 102(e) date  
DT Utility  
FS GRANTED  
LN.CNT 2254  
INCL INCLM: 424/143.100  
INCLM: 424/140.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;  
530/388.750; 530/388.800; 530/388.850  
NCLM: 424/143.100  
NCLM: 424/140.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;  
530/388.750; 530/388.800; 530/388.850  
IC [7]  
ICM: A61K039-395  
EXF 424/130.1; 424/143.1; 424/144.1; 424/809; 530/388.22; 530/388.7;  
530/388.75; 530/388.8; 530/388.85  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 26 OF 34 USPATFULL  
 AN 2001:75530 USPATFULL  
 TI Fas ligand-like protein, its production and use  
 IN Nishi, Kazunori, Ibaraki, Japan  
 Hikiuchi, Yukiko, Ibaraki, Japan  
 Shitani, Yasushi, Ibaraki, Japan  
 PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)  
 PI US 6235878 B1 20010522  
 AI WO 9803848 19980129 19970904 (8)  
 US 1997-913014 19970717  
 WO 1997-JP2480 19970904 PCT 371 date  
 19970904 PCT 102(e) date  
 JP 1996-191204 19960719  
 JP 1996-211695 19960809  
 JP 1997-19330 19970131  
 DT Utility  
 FS Granted  
 LN CNT 4854  
 INCL INCLM: 530/350.000  
 NCL NCLM: 530/350.000  
 IC [7]  
 ICM: C07K001-00  
 EXP 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 27 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
 AN 2001104651 EMBASE  
 TI Peyer's patches are required for oral tolerance to proteins.  
 AU Fujinashi K.; Dohi T.; Remnert P.D.; Yamamoto M.; Koga T.; Kiyono H.;  
 McChes J.R.  
 CS Fujinashi, Department of Oral Biology, Immunobiology Vaccine Center,  
 University of Alabama, BBRB 761, Birmingham, AL 35294-2170, United States.  
 KOHAROFU@uab.edu  
 SO Proceedings of the National Academy of Sciences of the United States of  
 America, (13 Mar 2001) 98/6 (3310-3315).  
 Refs: 44  
 ISSN: 0027-8424 CODEN: PNASA6  
 CY United States  
 FS Journal, Article  
 LA English  
 SL English

L3 ANSWER 28 OF 34 MEDLINE  
 AN 2001481745 MEDLINE  
 DN 21400854 PubMed ID: 11509623  
 TI Elimination of colonic patches with lymphotoxin beta  
 AU Dohi T.; Remnert P.D.; Fujinashi K.; Kiyono H.; Shirai Y.; Kawamura Y I;  
 Browning J L; McGhee J R  
 CS Department of Gastroenterology, Research Institute, International Medical  
 Center of Japan, Tokyo, Japan.. dohi@ri.imcj.go.jp  
 NC A118958 (NIAID)  
 A135932 (NIAID)  
 A13197 (NIDCR)  
 DE09837 (NIDCR)  
 DE12242 (NIDCR)  
 DK44240 (NIDCR)  
 P30DKS4781 (NIDDK)  
 SO JOURNAL OF IMMUNOLOGY, (2001 Sep 1) 167 (5) 2781-90.  
 CY United States  
 DT Journal, Article: (JOURNAL ARTICLE)  
 LA English

FS Abridged Index Medicus Journals; Priority Journals  
 EM 200112  
 ED Entered STM: 20010830  
 Last Updated on STM: 20020122  
 Entered Medline: 20011205

L3 ANSWER 29 OF 34 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. DUPLICATE  
 AN 2001:278934 BIOSIS  
 DN PREV200100278934  
 TI Recombinant, soluble LIGHT (HVEM ligand) induces increased IL-8 secretion  
 and growth arrest in A375 melanoma cells.  
 AU Hehlhans, Thomas; Maennel, Daniela N. (1)  
 (1) Institute of Pathology/Tumor Immunology, University of Regensburg,  
 F.-J.-Strauss-Allee 11, D-93042, Regensburg; daniela.maennel@klinik.uni-  
 regensburg.de Germany  
 SO Journal of Interferon and Cytokine Research, (May, 2001) Vol. 21, No. 5,  
 pp. 333-338. Print.  
 ISSN: 1079-9907.  
 DT Article  
 LA English  
 SL English

L3 ANSWER 30 OF 34 USPATFULL  
 AN 2000:146513 USPATFULL  
 TI Ligand for herpes simplex virus entry mediator and methods of use  
 IN Ware, Carl E.; Solana Beach, CA, United States  
 PA La Jolla Institute for Allergy and Immunology, La Jolla, CA, United  
 States (U.S. corporation) 20001031  
 PI US 6140467 19970730 (8)  
 AI US 1997-898234 19970730 (8)  
 PRAI US 1997-51964P 19970707 (60)  
 DT Utility  
 FS Granted  
 LN CNT 1522  
 INCL INCLM: 530/350.000  
 NCL NCLM: 530/350.000  
 IC [7]  
 ICM: C07K014-47  
 EXP 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 31 OF 34 MEDLINE  
 AN 2000219245 MEDLINE  
 DN 20219245 PubMed ID: 10754304  
 TI LIGHT, a TNF-like molecule, costimulates T cell proliferation and is  
 required for dendritic cell-mediated allogeneic T cell response.  
 AU Tamada K; Shimozaki K; Chapoval A I; Zhai Y; Su J; Chen S F; Hsieh S L;  
 Nagata S; Ni J; Chen L  
 CS Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic,  
 Rochester, MN 55905, USA.  
 SO JOURNAL OF IMMUNOLOGY, (2000 Apr 15) 164 (8) 4105-10.  
 CY United States  
 FS Journal, Article: (JOURNAL ARTICLE)  
 LA English  
 EM Abridged Index Medicus Journals; Priority Journals  
 ED Entered STM: 20000518  
 Last Updated on STM: 20000518  
 Entered Medline: 20000509

L3 ANSWER 32 OF 34 USPATFULL  
 AN 1999:81563 USPATFULL  
 TI Soluble lymphotoxin-beta. receptors and



anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

IN Browning, Jeffrey L., Brookline, MA, United States  
Benjamin, Christopher D., Beverly, MA, United States  
Hochman, Paula S., Brookline, MA, United States  
Biogen, Inc., Cambridge, MA, United States (U.S. corporation)  
US 5925351  
US 1995-505606  
19950720  
19950721 (8)  
US111111

FS Granted  
DT Utility  
LN.CNT 1968  
INCL INCLM: 424/143.100  
INCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000;  
530/395.000; 530/387.100; 530/388.220; 530/388.230; 530/388.730;  
530/388.850; 530/389.200  
NCLM: 424/143.100  
NCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000;  
530/387.100; 530/388.220; 530/388.230; 530/388.730; 530/388.850;  
530/389.200; 530/395.000  
IC [6]  
ICM: A61K039-395  
ICS: A61K038-16; C07K016-00; C07K016-28  
EXF 514/218; 530/395; 530/387.1; 530/388.22; 530/388.23; 530/388.73;  
530/388.85; 530/389.2; 424/143.1; 424/144.1; 424/145.1; 424/156.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2003 ACS  
AN 1996:588667 CAPLUS  
DN 125:219618  
TI Lymphotoxin- $\alpha$ - $\beta$  complexes and anti-lymphotoxin- $\beta$ .  
beta. receptor antibodies as anti-tumor agents  
IN Browning, Jeffrey L.; Meier, Werner; Benjamin, Christopher D.  
PA Biogen, Inc., USA  
SO PCT Int. Appl., 75 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1  
PATENT NO. KIND DATE APPLICATION NO. DATE  
PI WO 9622788 A1 19960801 WO 1996-US1386 19960126  
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, DE, DK, EE,  
ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV,  
LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
SG, SI  
RM: KE, LS, MM, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GT, HR, HU,  
CA 2211443 A1 19960801 CA 1996-2211443 19960126  
AU 9649704 A1 19960814 AU 1996-49704 19960126  
AU 765351 B2 20001012  
EP 809510 A1 19971203 EP 1996-906260 19960126  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE, MC, PT,  
IE, SI  
BR 9606808 A 19971230 BR 1996-6808 19960126  
CN 117702 A 19960325 CN 1996-192271 19960126  
JP 1051161 T2 19961215 JP 1996-523078 19960126  
NO 9703385 A 19970925 NO 1997-3385 19970722  
FI 9703118 A 19970925 FI 1997-3118 19970725  
US 6312691 B1 20011106 US 1996-875560 20010816  
US 2002090366 A1 20020711 US 2001-931402  
PRAI US 1995-378968 A2 19950126  
WO 1996-US1386 W 19960126  
US 1996-875560 A3 19960605

L3 ANSWER 34 OF 34 MEDLINE DUPLICATE 5

AN 96228308 MEDLINE  
DN 96228308 PubMed ID: 6642291  
TI Signaling through the lymphotoxin beta  
AU Browning J L; Mackowski K; Sizing I; Griffiths D; Zafari M; Benjamin C D;  
Meier W; Mackay F  
CS Department of Immunology and Inflammation, Biogen, Cambridge,  
Massachusetts 02142, USA.  
SO JOURNAL OF EXPERIMENTAL MEDICINE. (1996 Mar 1) 183 (3) 867-78.  
CY Journal code: 2985109R. ISSN: 0022-1007.  
DT United States  
LN.CNT 2115  
LA English  
FS Priority Journals  
EM 199607  
ED Entered STN: 19960726  
Last Updated on STN: 19970203  
Entered Medline: 19960716

=> d his  
(FILE 'HOME' ENTERED AT 12:32:53 ON 11 FEB 2003)  
FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, EMBASE, CAPLUS, USPATFULL'  
ENTERED AT 12:33:20 ON 11 FEB 2003  
L1 136 S LYMPHOTOXIN (A) BETA (A) RECEPTOR AND ANTIBOD?  
L2 42 S L1 AND INTERFERON?  
L3 34 DUP REM L2 (8 DUPLICATES REMOVED)  
L4 => s lymphotoxin (a) beta (a) receptor  
541 LYMPHOTOXIN (A) BETA (A) RECEPTOR  
L5 => s 14 and promoter?  
66 L4 AND PROMOT?  
=> dup rem 15  
PROCESSING COMPLETED FOR L5  
L6 43 DUP REM L5 (23 DUPLICATES REMOVED)  
=> d 1-43  
L6 ANSWER 1 OF 43 USPATFULL  
AN 2002:343531 USPATFULL  
TI Soluble lymphotoxin beta receptor and  
anti-lymphotoxin receptor and ligand antibodies as therapeutic agents  
for treatment  
IN Browning, Jeffrey L., Brookline, MA, UNITED STATES  
Hochman, Paula S., Newton, MA, UNITED STATES  
Remmert, Paul D., Millis, MA, UNITED STATES  
Mackay, Fabienne, Vauluse, AUSTRALIA  
CA 2211443 A1 20021226  
AU 9649704 A1 20021226  
US 2002197254 A1 20011031 (10)  
US 2001-3211 A1 20011031 (10)  
PRAI WO 1997-US19446 19971024  
US 1996-29060P 19961025 (60)  
DT Utility  
FS Application  
LN.CNT 2115  
INCL INCLM: 424/143.100  
INCLS: 514/012.000  
NCLM: 424/143.100  
NCLS: 514/012.000  
IC [7]  
ICM: A61K039-395

ICS: A61K038-17  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 43 USPTFULL  
AN 2002:272856 USPTFULL  
TI TNF receptor-like molecules and uses thereof  
IN Theill, Lars Eyde, Thousand Oaks, CA, UNITED STATES  
Yen, Richard, Ithaca, NY, UNITED STATES  
Slibiger, Scott Michael, Woodland Hills, CA, UNITED STATES  
Yu, Gang, Thousand Oaks, CA, UNITED STATES  
Senaldi, Giorgio, Thousand Oaks, CA, UNITED STATES

PI US 2002:50977 A1 20021017  
AI US 2001-948018 A1 20010905 (9)  
PRAI US 2000-230191P 20000905 (60)  
DT Utility  
FS APPLICATION

IN.CNT 5781  
INCL INCLM: 435/069.100  
INCLM: 435/325.000; 435/320.100; 530/350.000; 536/023.500; 435/194.000  
NCLM: 435/069.100  
NCLS: 435/325.000; 435/320.100; 530/350.000; 536/023.500; 435/194.000

IC [7]  
ICM: C12P021-02  
ICS: C12N005-06; C07H021-04; C12N009-12  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 43 USPTFULL  
AN 2002:272468 USPTFULL

TI Tumor necrosis factor receptors  $\alpha$ 1 and  $\beta$ 2  
IN Gentz, Reiner L., Rockville, MD, UNITED STATES  
Ebner, Reinhard, Galtersburg, MD, UNITED STATES  
Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES  
Feng, Ping, Galtersburg, MD, UNITED STATES  
Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. Corporation)

PI US 2002:50583 A1 20021017  
AI US 2001-935727 A1 20010824 (9)  
R1 Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING

PRAI US 2001-303224P 20010706 (60)  
US 2000-252131P 20001121 (60)  
US 2000-227598P 20000825 (60)  
US 1999-168235P 19991201 (60)  
US 1999-146371P 19990802 (60)  
US 1999-131964P 19990430 (60)  
US 1999-131270P 19990427 (60)  
US 1999-124092P 19990312 (60)  
US 1999-121774P 19990304 (60)  
US 1997-35496P 19970114 (60)

DT Utility  
FS APPLICATION  
IN.CNT 12989  
INCL INCLM: 424/178.100  
INCLM: 530/389.100  
NCLM: 424/178.100  
NCLS: 530/389.100  
IC [7]  
ICM: A61K039-395  
ICS: C07K016-46  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 43 USPTFULL  
AN 2002:259408 USPTFULL

TI Gene expression profiles in liver cancer  
IN Horne, Darci T., Galtersburg, MD, UNITED STATES  
Scherf, Uwe, Galtersburg, MD, UNITED STATES  
Vockley, Joseph, Damascus, MD, UNITED STATES  
PI US 2002:42981 A1 20021003  
AI US 2001-880107 A1 20010614 (9)  
PRAI US 2000-211379P 20000614 (60)  
US 2000-237054P 20001002 (60)

DT Utility  
FS APPLICATION  
IN.CNT 15937  
INCL INCLM: 514/044.000  
INCLM: 435/006.000  
NCLM: 514/044.000  
NCLS: 435/006.000

IC [7]  
ICM: A61K048-00  
ICS: C12Q001-68  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 43 USPTFULL  
AN 2002:235448 USPTFULL

TI Human tumor necrosis factor receptor-like protein 8  
IN Ni, Jian, Rockville, MD, UNITED STATES  
Moore, Paul A., Germantown, MD, UNITED STATES

PI US 2002:27637 A1 20020912  
AI US 2001-768779 A1 20010125 (9)  
R1 Continuation of Ser. No. US 1998-86582, filed on 29 May 1998, ABANDONED  
PRAI US 1997-48020P 19970529 (60)  
DT Utility  
FS APPLICATION

IN.CNT 3860  
INCL INCLM: 435/069.100  
INCLM: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
NCLM: 435/069.100  
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500

IC [7]  
ICM: C07K014-715  
ICS: C12P021-02; C12N005-06; C07H021-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 43 USPTFULL  
AN 2002:235426 USPTFULL

TI TRAF-3 deletion isoforms and uses thereof  
IN Lederman, Seth, New York, NY, UNITED STATES  
Eynhoeven, Winfried Van, Belport, NY, UNITED STATES

PI US 2002:27615 A1 20020912  
AI US 2001-950902 A1 20010910 (9)  
R1 Continuation of Ser. No. WO 2000-US6503, filed on 10 Mar 2000, UNKNOWN  
PRAI US 1999-268544, filed on 11 Mar 1999, PENDING

DT Utility  
FS APPLICATION  
IN.CNT 4140  
INCL INCLM: 435/007.210  
INCLM: 435/183.000; 435/325.000; 435/320.100; 530/350.000; 536/023.200  
NCLM: 435/007.210  
NCLS: 435/183.000; 435/325.000; 435/320.100; 530/350.000; 536/023.200

IC [7]  
ICM: G01N033-567  
ICS: C07H021-04; C12N009-00; C07K014-705  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 43 USPATFULL  
AN 2002:228312 USPATFULL  
TI Treatment of autoimmune disease  
IN Faustman, Denise, Weston, MA, UNITED STATES  
PI US 2002:234722 A1 20020905  
RI US 2001-768769 A1 20010123 (9)  
ABANDONED  
PRAI US 1999-123738P 19990310 (60)  
DT Utility  
FS APPLICATION  
INCL 1830  
INCLM: 514/044.000  
NCLM: 435/005.000; 435/235.100; 435/325.000; 435/007.920; 435/069.500  
NCLM: 514/044.000  
NCLM: 435/005.000; 435/235.100; 435/325.000; 435/007.920; 435/069.500  
IC [7]  
ICM: C12Q001-70  
ICS: G01N033-53; G01N033-517; G01N033-543; A61K031-70; A01N043-04;  
C12P021-02; C12N007-00; C12N007-01; C12N005-00; C12N005-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 43 USPATFULL  
AN 2002:206139 USPATFULL  
TI Compositions and methods for the therapy and diagnosis of colon cancer  
IN Pyle, Ruth A., Seattle, WA, UNITED STATES  
XU Jiangchun, Bellevue, WA, UNITED STATES  
PA Corixa Corporation, Seattle, WA, UNITED STATES  
PI US 2002:10832 A1 20020815  
AI US 2001-919580 A1 20010730 (9)  
US 2001-302702P 20010703 (60)  
US 2001-277495P 20010320 (60)  
US 2000-237406P 20001002 (60)  
US 2000-223265P 20000803 (60)  
DT Utility  
FS APPLICATION  
INCL 5425  
INCLM: 435/007.100  
NCLM: 536/023.100; 530/350.000  
NCLM: 435/007.100  
NCLM: 536/023.100; 530/350.000  
IC [7]  
ICM: G01N033-53  
ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 43 USPATFULL  
AN 2002:171619 USPATFULL  
TI Anti-lymphotoxin-beta receptor antibodies  
IN as anti-tumor agents  
Browning, Jeffrey L., Brookline, MA, UNITED STATES  
Meier, Werner, Burlington, MA, UNITED STATES  
PI US 2002:090366 A1 20020711  
RI US 2001-931402 A1 20010816 (9)  
ABANDONED  
PRAI US 1998-875560 filed on 5 Jun 1998, PATENTED A 371  
of International Ser. No. WO 1996-051386, filed on 26 Jan 1996, UNKNOWN  
Continuation-in-part of Ser. No. US 1995-378968, filed on 26 Jan 1995,  
PENDING  
DT Utility  
FS APPLICATION  
INCL 1764  
INCLM: 424/094.100  
INCLM: 424/178.100

NCL NCLM: 424/094.100  
NCLM: 424/178.100  
IC [7]  
ICM: A61K039-395  
ICS: A61K039-40  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 43 USPATFULL  
AN 2002:157048 USPATFULL  
TI APOPTOSIS INDUCING MOLECULE II AND METHODS OF USE  
IN EBER, REINHARD, GAITHERSBURG, MD, UNITED STATES  
YU, GUO-LIANG, BERKELEY, CA, UNITED STATES  
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES  
ZHANG, JUN, BETHESDA, MD, UNITED STATES  
ULRICH, STEPHEN, ROCKVILLE, MD, UNITED STATES  
ZHAI, YIFAN, GAITHERSBURG, MD, UNITED STATES  
PA Human Genome Sciences (U.S. corporation)  
PI US 2002:081647 A1 20020627  
AI US 1999-252656 A1 19990219 (9)  
US 1999-252656 A1 19990219 (9)  
Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998,  
PENDING Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan  
1998, ABANDONED Continuation-in-part of Ser. No. US 1997-822953, filed  
on 21 Mar 1997, ABANDONED  
PRAI US 1998-754092 19980220 (60)  
US 1998-13923P 19960322 (60)  
US 1996-30157P 19961031 (60)  
DT Utility  
FS APPLICATION  
INCL 6195  
INCLM: 435/069.100  
NCLM: 530/350.000; 530/399.000; 514/012.000; 536/023.500  
NCLM: 514/012.000  
NCLM: 530/300.000; 530/324.000; 530/350.000  
IC [7]  
ICM: A61K038-18  
ICS: C12P021-06; C07H021-04; C07K014-00; G01N033-53  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 43 USPATFULL  
AN 2002:126357 USPATFULL  
TI APOPTOSIS INDUCING MOLECULE II  
IN EBER, REINHARD, GAITHERSBURG, MD, UNITED STATES  
YU, GUO-LIANG, DARTMOUTH, MD, UNITED STATES  
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES  
ULRICH, STEPHEN, ROCKVILLE, MD, UNITED STATES  
PA Human Genome Sciences, Inc. (U.S. corporation)  
PI US 2002:064869 A1 20020530  
US 6479254 B2 20021112  
US 1998-27287 A1 19980220 (9)  
Continuation-in-part of Ser. No. US 1997-822953, filed on 21 Mar 1997,  
ABANDONED  
PRAI US 1996-30157P 19961031 (60)  
US 1996-13923P 19960322 (60)  
DT Utility  
FS APPLICATION  
INCL 4242  
INCLM: 435/320.100  
NCLM: 435/069.100; 435/325.000; 536/023.500  
NCLM: 435/069.100; 435/320.100; 435/325.000; 530/324.000; 536/023.400;  
NCLM: 536/023.500; 536/024.100; 930/144.000  
IC [7]  
ICM: C12N015-63  
ICS: C07H021-04; C12N015-00; C12N015-74; C12N005-06; C12N015-70;

C12N015-09  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 43 USPATFULL  
AN 2002:119846 USPATFULL  
TI Human G-protein Chemokine receptor (CCRS) HDGNR10  
IN Rosen, Craig A., Laytonville, MD, UNITED STATES  
Roschke, Viktor, Rockville, MD, UNITED STATES  
Li, Yi, Sunnyvale, CA, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
PI US 2002061834 A1 20020523  
AI US 2001-779880 A1 20010209 (9)  
PRAI US 2000-181258P 20000209 (60)  
US 2000-187999P 20000309 (60)  
US 2000-234336P 20000922 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 18667  
INCL INCLM: 514/001.000  
INCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100  
NCLM: 514/001.000  
NCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100  
IC [7]  
ICM: A61K031-00  
ICS: C07H021-04; C07K014-705; C12N005-06; C12P021-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 43 USPATFULL  
AN 2002:92268 USPATFULL  
TI Human G-protein Chemokine Receptor HDGNR10  
IN Rosen, Craig A., Laytonville, MD, UNITED STATES  
Roschke, Viktor, Rockville, MD, UNITED STATES  
Li, Yi, Sunnyvale, CA, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
PI US 2002048786 A1 20020425  
AI US 2001-779879 A1 20010209 (9)  
PRAI US 2000-181258P 20000209 (60)  
US 2000-187999P 20000309 (60)  
US 2000-234336P 20000922 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 17969  
INCL INCLM: 435/069.100  
INCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000  
NCLM: 435/069.100  
NCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000  
IC [7]  
ICM: G01N033-53  
ICS: G01N033-567; A61K038-00; C07H021-04; C12P021-06; A61K039-395;  
C12N005-02; C12N005-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 43 USPATFULL  
AN 2002:67215 USPATFULL  
TI Method for detecting hepatitis C  
IN Budkowska, Agata, Clamart, FRANCE  
Maillard, Patrick, Montlhery, FRANCE  
Bromert, Christian, Fresnes, FRANCE  
Gounon, Pierre, Noisieu, FRANCE  
Nikliewicz, Jadwiga, Komorow, POLAND  
Grainic, Radu, Jouy En Josas, FRANCE  
PA INSTITUT PASTEUR, Paris Cedex, FRANCE, 75724 (non-U.S. corporation)  
PI US 2002037868 A1 20020328  
AI US 2001-880945 A1 20010615 (9)  
PRAI US 2000-549685, filed on 14 Apr 2000,  
R11 Continuation-in-part of Ser. No. US 2000-549685, filed on 14 Apr 2000,

PENDING  
PRAI US 1999-129319P 19990414 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1656  
INCL INCLM: 514/044.000  
INCLS: 435/005.000; 435/007.950; 435/091.330; 435/975.000  
NCLM: 514/044.000  
NCLS: 435/005.000; 435/007.950; 435/091.330; 435/975.000  
IC [7]  
ICM: C12Q001-70  
ICS: G01N033-53; G01N033-537; G01N033-543; A61K031-70; A01N043-04;  
C12P019-34  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 43 USPATFULL  
AN 2002:26858 USPATFULL  
TI Antagonists of tweak and of tweak receptor and their use to treat  
IN Immunological disorders  
PI Renner, Paul, Mills, MA, UNITED STATES  
AI US 2002015703 A1 20020207  
PRAI US 2001-905810 A1 20010713 (9)  
MO 2000-US1044 20000114  
US 1999-116168P 19990115 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1303  
INCL INCLM: 424/143.100  
NCLM: 424/143.100  
IC [7]  
ICM: A61K039-395  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 43 USPATFULL  
AN 2002:22092 USPATFULL  
TI Nucleic acid sequences associated with aging, particularly skin aging  
IN Butner, Glenna C., Seattle, WA, UNITED STATES  
Brown, Joseph P., Seattle, WA, UNITED STATES  
Pritchard, David, Seattle, WA, UNITED STATES  
PI US 2002012927 A1 20020131  
AI US 2001-802718 A1 20010308 (9)  
PRAI US 2000-188584P 20000310 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2368  
INCL INCLM: 435/006.000  
INCLS: 435/007.210  
NCLM: 435/006.000  
NCLS: 435/007.210  
IC [7]  
ICM: C12Q001-68  
ICS: G01N033-567; A61K031-665  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 43 USPATFULL  
AN 2002:8587 USPATFULL  
TI Multivalent antibodies and uses thereof  
IN Miller, Kathy L., San Francisco, CA, UNITED STATES  
Presta, Leonard G., San Francisco, CA, UNITED STATES  
PA GENENTECH, INC. (U.S. corporation)  
PI US 2002004587 A1 20020110  
AI US 2001-813341 A1 20010320 (9)  
PRAI US 2000-195819P 20000411 (60)  
DT Utility  
FS APPLICATION

LN.CNT 4913  
INCL INCLM: 530/388.800  
NCLM: 536/023.500; 435/325.000; 435/334.000; 424/143.100  
NCLM: 530/388.800  
NCLM: 536/023.500; 435/325.000; 435/334.000; 424/143.100  
IC [7]  
ICM: C07K016-28  
ICS: A61K039-395; C07H021-04; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 43 USPATFULT  
AN 2002:188392 USPATFULT  
TI TRAF family molecules, polynucleotides encoding them, and antibodies  
against them  
IN Nakano, Moromi, Yokohama, Japan  
Yagita, Hideo, Tokyo, Japan  
Okumura, Ko, 9-2-610, Azusawa 3-chome, Itabashi-ku, Tokyo 174-0051,  
Japan  
PA Okumura, Ko, Tokyo, Japan (non-U.S. individual)  
PI US 6426403 B1 20020730  
AI US 1998-138277 19980818 (9)  
RUI Continuation-in-part of Ser. No. WO 1997-JP512, filed on 24 Feb 1997  
PRAI JP 1996-34674 19960222  
DT Utility  
FS GRANTED  
LN.CNT 1694  
INCL INCLM: 530/350.000  
NCLM: 530/351.000; 435/069.100; 536/023.100  
NCLM: 530/350.000  
NCLM: 530/350.000  
NCLM: 435/069.100; 530/351.000; 536/023.100  
IC [7]  
ICM: C07K014-52  
ICS: C07H021-04; C12N015-00  
EXF 530/350.000; 530/350.000; 530/351.000; 435/183.435/174; 435/69.1.536/23.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 43 USPATFULT  
AN 2002:152777 USPATFULT  
TI Nucleic acid encoding a TRAF-3 deletion isoform  
IN Lederman, Seth, New York, NY, United States  
Van Eynhoven, Winfried, BaySide, NY, United States  
PA The Trustees of the University in the City of New York, New York, NY,  
United States (U.S. corporation)  
PI US 6410710 B1 20020625  
AI US 1999-268544 19990311 (9)  
DT Utility  
FS GRANTED  
LN.CNT 3011  
INCL INCLM: 536/023.500  
NCLM: 536/023.100; 435/320.100  
NCLM: 536/023.500  
NCLM: 435/320.100; 536/023.100  
IC [7]  
ICM: C07H021-04  
ICS: C12N015-11; C12N015-63  
EXF 536/23.1.536/23.5.435/320.1.424/93.1.514/44  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 43 USPATFULT  
AN 2002:136562 USPATFULT  
TI Soluble lymphotoxin-beta receptors as  
therapeutic agents for the treatment of immunological disease  
IN Browning, Jeffrey L., Brookline, MA, United States  
Benjamin, Christopher D., Beverly, MA, United States

PA Hochman, Paula S., Newton, MA, United States  
Bigen, Inc., Cambridge, MA, United States (U.S. corporation)  
PI US 6403087 B1 20020611  
MO 9703687 19970206 19980608 (9)  
AI US 1998-166 19960719  
WO 1996-US12010  
RUI Continuation-in-part of Ser. No. US 1995-505606, filed on 21 Jul 1995,  
now patented, Pat. No. US 5925351  
DT Utility  
FS GRANTED  
LN.CNT 1983  
INCL INCLM: 424/134.100  
NCLM: 424/134.100; 424/133.100; 514/002.000; 514/008.000; 530/387.100;  
530/387.300  
NCLM: 424/134.100  
NCLM: 424/133.100; 514/002.000; 514/008.000; 530/387.100; 530/387.300  
IC [7]  
ICM: A61K039-395  
ICS: A61K038-16  
EXF 424/148.1.424/144.1.424/145.1.424/156.1.514/2.514/8.530/395;  
530/387.1.530/388.22.530/388.23.530/388.73.530/388.85.530/389.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 43 MEDLINE  
AN 2002378234 MEDLINE  
DN 22119432 PubMed ID: 12124338  
TI Lymphotoxin-beta receptor immune interaction  
promotes tumor growth by inducing angiogenesis.  
AU Cerniianu Grigore, Gaba Markus, Steinhauer Markus, Nedospasov Sergei A,  
Pfeffer Klaus, Mannel Daniela N  
CS Department of Pathology/Tumor Immunology, University of Regensburg,  
D-93042 Regensburg, Germany.  
SO CANCER RESEARCH. (2002 Jul 15) 62 (14) 4034-40.  
Journal code: 2984705R. ISSN: 0008-5472.  
CY United States  
DT Journal, Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200208  
ED Entered STN: 20020719  
Last Updated on STN: 20020814  
Entered Medline: 20020813

L6 ANSWER 22 OF 43 MEDLINE  
AN 2002415478 MEDLINE  
DN 22159812 PubMed ID: 12169272  
TI Lymphotoxin beta receptor induces  
interleukin 8 gene expression via NF-kappaB and AP-1 activation.  
AU Chang Yung-Hsin; Hsieh Shie-Liang; Chen Wei-Chieh; Lin Wan-Wan  
Department of Pharmacology, College of Medicine, National Taiwan  
University, Taipei, Taiwan.  
SO EXPERIMENTAL CELL RESEARCH. (2002 Aug 15) 278 (2) 166-74.  
Journal code: 0373226. ISSN: 0014-4827.  
CY United States  
DT Journal, Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200209  
ED Entered STN: 20020810  
Last Updated on STN: 20021002  
Entered Medline: 20020913

L6 ANSWER 23 OF 43 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 2003:5196 BIOSIS  
 DN PREV20030005196  
 TI Lymphotoxin-beta receptor activation  
 AU Hehlhans, T. (1); Stoelcker, B. (1); Stoffer, P. (1); Steinbauer, M.;  
 Pfeiffer, K.; Maennel, D. N. (1)  
 CS (1) Institute of Pathology/Tumor Immunology, Technical University of  
 Munich, Munich, Germany  
 SO Journal of Interferon and Cytokine Research, (2002) Vol. 22, No.  
 Supplement 1, pp. S-113. Print.  
 Meeting Info.: Joint Meeting of the International Society for Interferon  
 and Cytokine Research, the International Cytokine Society, the Society for  
 Leukocyte Biology, and the European Cytokine Society on Cytokines and  
 Interferons Turin, Italy October 06-10, 2002 International Society for  
 Interferon and Cytokine Research  
 . ISSN: 1079-9907.

DT Conference  
 LA English

L6 ANSWER 24 OF 43 USPATFUL  
 AN 2001:23143 USPATFUL  
 TI Arrays for identifying agents which mimic or inhibit the activity of  
 interferons  
 IN Silverman, Robert H., Beachwood, OH, United States  
 Williams, Bryan R. G., Cleveland, OH, United States  
 Der, Sandy, Cleveland, OH, United States  
 PA The Cleveland Clinic Foundation, Cleveland, OH, United States (U.S.  
 corporation)  
 PI US 6313396 B1 20011218  
 AI US 1999-405438 19990923 (9)  
 PRAI US 1998-101497P 19980923 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 9639  
 INCL INCLM: 435/006.000  
 NCL INCLM: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310  
 NCLM: 435/006.000  
 NCLS: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310

IC ICM: C120001-68  
 ICS: C12M001-36; C07H021-04  
 EXF 435/6; 435/287.2; 536/23.1; 536/24.31; 536/23.52  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 43 USPATFUL  
 AN 2001:19600 USPATFUL  
 TI Lymphotoxin-.alpha./beta. complexes and anti-lymphotoxin-.beta. receptor  
 antibodies as anti-tumor agents  
 IN Browning, Jeffrey L., 32 Milton Rd., Brookline, MA, United States 02146  
 Weiler, Werner, 31 Bedford St., Burlington, MA, United States 01803  
 Benjamin, Christopher D., 2 Oak Hill La., Beverly, MA, United States  
 01915  
 PI US 6312691 B1 20011106  
 AI US 9622788 19960801  
 WO 1996-075560  
 MO 1996-US1386

DT Utility  
 FS GRANTED  
 LN.CNT 2254  
 INCL INCLM: 424/143.100  
 INCLM: 424/130.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;  
 530/388.750; 530/388.800; 530/388.850  
 NCLM: 424/143.100

NCLM: 424/130.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;  
 530/388.750; 530/388.800; 530/388.850

IC ICM: A61K039-395  
 EXF 424/130.1; 424/143.1; 424/144.1; 424/809; 530/388.22; 530/388.7;  
 530/388.75; 530/388.8; 530/388.85  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 26 OF 43 USPATFUL  
 AN 2001:75530 USPATFUL  
 TI Fas ligand-like protein, its production and use  
 IN Nishi, Kazunori, Ibaraki, Japan  
 Hikichi, Yukiko, Ibaraki, Japan  
 Shintani, Yasushi, Ibaraki, Japan  
 PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)  
 PI US 6235878 B1 20010522  
 WO 9803648 19980129  
 MO 1997-JP2480

AI 19970904 (8)  
 19970717  
 19970904  
 19970904 PCT 371 date  
 19970904 PCT 102(e) date

PRAI JP 1996-191204 19960719  
 JP 1996-211695 19960809  
 JP 1997-19330 19970131

DT Utility  
 FS GRANTED  
 LN.CNT 4854  
 INCL INCLM: 530/350.000  
 NCLM: 530/350.000  
 IC ICM: C07K001-00  
 EXF 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 43 USPATFUL  
 AN 2001:44016 USPATFUL  
 TI Proteins capable of regulating NF-kappa.B JNK and apoptosis pathways  
 and methods of using the same  
 IN Chaudhary, Preet M., Dallas, TX, United States  
 Hood, Leroy, Seattle, WA, United States  
 PA University of Washington/Stowers Institute for Medical Research, United  
 States (U.S. corporation)  
 PI US 6207458 B1 20010327  
 AI US 1998-74044 19980507 (9)  
 DT Utility  
 FS GRANTED  
 LN.CNT 1982  
 INCL INCLM: 435/503.000  
 INCLM: 435/004.000; 435/007.100; 435/007.720; 435/018.000; 435/023.000;  
 435/040.500; 435/040.510; 435/040.520  
 NCLM: 435/004.000  
 NCLS: 435/004.000; 435/007.100; 435/007.720; 435/018.000; 435/023.000;  
 435/040.500; 435/040.510; 435/040.520

IC ICM: C120001-37  
 ICS: C12M001-90; G01N033-567; G01N033-18; G01N033-53  
 EXF 435/503; 435/4; 435/7.1; 435/7.72; 435/18; 435/23; 435/40.5; 435/40.51;  
 435/40.52  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 43 CAPLUS COPYRIGHT 2003 ACS  
 AN 2001:100086 CAPLUS  
 DN 134:265112  
 TI Signal via lymphotoxin-.beta.R on bone marrow stromal cells is required  
 for an early checkpoint of NK cell development

AU Wu, Qiang; Sun, Yongjian; Wang, Jing; Lin, Xiaogui; Wang, Yang; Peng, Lyile  
 E.; Pfeiffer, Agnes; Pfeiffer, Klaus; Fu, Yang-Xin  
 CS Department of Pathology, University of Chicago, Chicago, IL, 60637, USA  
 SO Journal of Immunology (2001), 166(3), 1684-1689  
 CODEN: JOIMAS; ISSN: 0022-1767  
 PB American Association of Immunologists  
 DT Journal  
 LA English  
 RE.CNT 28  
 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 29 OF 43 MEDLINE  
 AN 2001246642 PubMed ID: 11238592  
 DN 21136241  
 TI Molecular basis for hematopoietic/mesenchymal interaction during  
 AU Honda K; Nakano H; Yoshida H; Nishikawa S; Rennett P; Ikuta K; Tamechika  
 M; Yamaguchi K; Fukumoto T; Chiba T; Nishikawa S I  
 CS Department of Molecular Genetics, Graduate School of Medicine, Kyoto  
 University, Syogoin-Kawaharacho 53, Sakyo-ku, Kyoto 606-8507, Japan..  
 SO JOURNAL OF EXPERIMENTAL MEDICINE. (2001 Mar 5) 193 (5) 621-30.  
 CY Journal code: 29851098. ISSN: 0022-1007.  
 DT United States  
 LA English  
 DT Journal Article: (JOURNAL ARTICLE)  
 FS Priority Journals  
 EM 200105  
 Entered STN: 20010517  
 Last Updated on STN: 20010517  
 Entered Medline: 20010510

L6 ANSWER 30 OF 43 MEDLINE  
 AN 2001331753 PubMed ID: 11399522  
 DN 21292766  
 TI Functional characterization of the mouse lymphotoxin-  
 AU Muller P; Mannel D N; Hehlhans T  
 CS Institute of Pathology and Tumor Immunology, University of Regensburg,  
 D-93042 Regensburg, Germany.  
 SO EUROPEAN CYTOKINE NETWORK. (2001 Apr-Jun) 12 (2) 325-30.  
 CY Journal code: 9100879. ISSN: 1148-5493.  
 DT France  
 DT Journal Article: (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200109  
 Entered STN: 20010910  
 Last Updated on STN: 20010910  
 Entered Medline: 20010906

L6 ANSWER 31 OF 43 CAPLUS COPYRIGHT 2003 ACS  
 AN 2001:570450 CAPLUS  
 DN 135:287475  
 TI Bridging the NFAT and NF-kappa B families: NFATs dimerization regulates  
 AU Lopez-Rodriguez, Cristina; Abramun, Jose; Jin, Lei; Kakeman, Andrew S.;  
 Michino, Mayako; Rao, Anjana  
 CS The Center for Blood Research and Department of Pathology, Harvard Medical  
 School, Boston, MA, 02115, USA  
 SO Immunity (2001), 15(1), 47-58  
 CODEN: IUNIEH; ISSN: 1074-7613  
 PB Cell Press  
 DT Journal  
 LA English

RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 32 OF 43 USPATFULL  
 AN 2000:168142 USPATFULL  
 TI Proteins capable of regulating NF-kappa.B, JNK and apoptosis pathways  
 AU Chaudhary, Preet M.; Dallas, TX, United States  
 IN Hood, Leroy, Seattle, WA, United States  
 PA University of Washington, Seattle, WA, United States (U.S. corporation)  
 PI (U.S. corporation)  
 AI US 6160095 20001212  
 RLT US 1999-382155 19990824 (9)  
 DT Division of Ser. No. US 1998-74044, filed on 7 May 1998  
 FS Utility  
 LN.CNT 2638  
 INCL INCLM: 530/350.000  
 NCL NCLM: 530/350.000  
 IC [7]  
 ICM: C07K014-435  
 ICS: C07K014-47  
 EXP 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 33 OF 43 USPATFULL  
 AN 2000:146513 USPATFULL  
 TI Ligand for herpes simplex virus entry mediator and methods of use  
 AU Ware, Carl E.; Solana Beach, CA, United States  
 IN La Jolla Institute for Allergy and Immunology, La Jolla, CA, United  
 States (U.S. corporation)  
 PI US 6140467 20001031  
 AI US 1997-898234 19970730 (8)  
 PRAI US 1997-51964P 19970707 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 1522  
 INCL INCLM: 530/350.000  
 NCL NCLM: 530/350.000  
 IC [7]  
 ICM: C07K014-47  
 EXP 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 34 OF 43 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
 AN 2001:210641 BIOSIS  
 DN PREV200100210641  
 TI Lymphotoxin-beta receptor activation  
 AU Hehlhans, T. (1); Stoelcker, B. (1); Steinbauer, M.; Pfeiffer, K.; Maennel,  
 D. N. (1)  
 CS (1) Department of Tumor Immunology, Institute of Pathology, University of  
 Regensburg, Regensburg Germany  
 SO Immunobiology, (November, 2000) Vol. 203, No. 1-2, pp. 405. print.  
 Meeting Info.: Joint Annual Meeting of the German and Dutch Societies of  
 Immunology Dinseldorf, Germany November 29-December 02, 2000  
 ISSN: 0171-2985.  
 DT Conference  
 LA English  
 SL English

L6 ANSWER 35 OF 43 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
 AN 2000:408684 BIOSIS  
 DN PREV200000408684

TI Characterization of the mouse lymphotoxin-beta receptor promoter.  
 AU Mueller, P. (1); Hehlhans, T. (1); Maennel, D. N. (1)  
 CS (1) Institute of Pathology/Tumorimmunology, University of Regensburg, Regensburg Germany  
 SO Scandinavian Journal of Immunology, (June, 2000) Vol. 51, No. Supplement 1, pp. 60. print.  
 DT Meeting Info.: 8th International TNF Congress, Conference on Tumor Necrosis Factor and Related Molecules Scientific Advances and Medical Applications Trondheim, Norway May 14-18, 2000  
 LA English  
 SL English  
 L6 ANSWER 36 OF 43 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
 AN 2000/416045 BIOSIS  
 DN PREV20000416045  
 TI Lymphotoxin-beta receptor activation  
 AU Hehlhans, T. (1); Stoeckler, B. (1); Steinbauer, M.; Pfeffer, K.; Maennel, D. N. (1)  
 CS (1) Institute of Pathology/Tumorimmunology, Technical University of Munich, Munich Germany  
 SO Scandinavian Journal of Immunology, (June, 2000) Vol. 51, No. Supplement 1, pp. 39. print.  
 DT Meeting Info.: 8th International TNF Congress, Conference on Tumor Necrosis Factor and Related Molecules Scientific Advances and Medical Applications Trondheim, Norway May 14-18, 2000  
 LA English  
 SL English  
 L6 ANSWER 37 OF 43 CAPLUS COPYRIGHT 2003 ACS  
 AN 2000/477615 CAPLUS  
 DN 133:23392  
 TI Detection of protein-protein interactions using a green fluorescent protein-based mammalian two-hybrid system  
 AU Focin-Mieczek, M.; Rottmann, M.; Rehg, G.; Rupp, S.; Johannes, F.-J.; Fraunhofer Institute for Interfacial Engineering and Biotechnology, Stuttgart, 70569, Germany  
 CS Biotechniques (2000), 29 (1), 22-24, 26  
 SO CODEN: BTNDOD; ISSN: 0736-6205  
 PB Eaton Publishing Co.  
 DT Journal  
 LA English  
 RE.CNT 11  
 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

INCL: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000; 530/395.000; 530/387.100; 530/388.220; 530/388.230; 530/388.720; 530/388.850; 530/389.200  
 NCL NCLM: 424/143.100  
 NCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000; 530/387.100; 530/388.220; 530/388.230; 530/388.720; 530/388.850; 530/389.200; 530/395.000  
 IC [6]  
 ICM: A6IK039-395  
 ICS: A6IK038-16; C07K016-00; C07K016-28  
 EXF 514/218; 530/395; 530/387.1; 530/388.22; 530/388.23; 530/388.73; 530/388.85; 530/389.2; 424/143.1; 424/144.1; 424/145.1; 424/156.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L6 ANSWER 39 OF 43 CAPLUS COPYRIGHT 2003 ACS  
 AN 1999/456745 CAPLUS  
 DN 131:241771  
 TI Requirement for membrane lymphotoxin in natural killer cell development  
 AU Iizuka, Koho; Chaplin, David D.; Wang, Yang; Wu, Qiang; Pegg, Lytle E.; Yokoyama, Wayne M.; Fu, Yang-Xin  
 CS Departments of Internal Medicine and Pathology, Howard Hughes Medical Institute, and Center for Immunology, Washington University School of Medicine, St. Louis, MO, 63110, USA  
 SO Proceedings of the National Academy of Sciences of the United States of America (1999), 96 (11), 6336-6340  
 CODEN: PNASDA; ISSN: 0027-8424  
 PB National Academy of Sciences  
 DT Journal  
 LA English  
 RE.CNT 28  
 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

INCL: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000; 530/395.000; 530/387.100; 530/388.220; 530/388.230; 530/388.720; 530/388.850; 530/389.200  
 NCL NCLM: 424/143.100  
 NCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000; 530/387.100; 530/388.220; 530/388.230; 530/388.720; 530/388.850; 530/389.200; 530/395.000  
 L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2003 ACS  
 AN 1999/594139 CAPLUS  
 DN 131:298517  
 TI The requirement of membrane lymphotoxin for the presence of dendritic cells in lymphoid tissues  
 AU Wu, Qiang; Wang, Yang; Wang, Jing; Hedgeman, Elizabeth O.; Browning, Jeffrey L.; Fu, Yang-Xin  
 CS Department of Pathology, The University of Chicago, Chicago, IL, 60637, USA  
 SO Journal of Experimental Medicine (1999), 190 (5), 629-638  
 CODEN: JEMEDV; ISSN: 0022-1007  
 PB Rockefeller University Press  
 DT Journal  
 LA English  
 RE.CNT 32  
 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

INCL: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000; 530/395.000; 530/387.100; 530/388.220; 530/388.230; 530/388.720; 530/388.850; 530/389.200  
 NCL NCLM: 424/143.100  
 NCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000; 530/387.100; 530/388.220; 530/388.230; 530/388.720; 530/388.850; 530/389.200; 530/395.000  
 L6 ANSWER 41 OF 43 MEDLINE  
 AN 1998216728 MEDLINE  
 DN 98216728 PubMed ID: 9557650  
 TI Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.  
 AU Zhu N; Khoshnaw A; Schneider R; Matsumoto M; Demert G; Ware C; Lai M M  
 CS Department of Molecular Microbiology and Immunology, University of Southern California School of Medicine, Los Angeles 90033, USA.  
 SO JOURNAL OF VIROLOGY, (1998 May) 72 (5) 3691-7.  
 CY United States  
 DT Journal; Article: (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199805  
 ED Entered STM: 19980529



Last Updated on STN: 20021008  
Entered Medline: 19980520

L6 ANSWER 42 OF 43 CAPLUS COPYRIGHT 2003 ACS  
AN 1998:417179 CAPLUS  
DN 129:160479  
TI Effects of tumor necrosis factor and lymphotoxin on peripheral lymphoid  
tissue development  
AU Ettinger, Rachel; Mebius, Reina; Browning, Jeffrey L.; Michie, Sara A.;  
Van Tuijl, Silvy; Kraal, George; Van Ewijk, Willem; McDevitt, Hugh O.  
CS Dep. Microbiol. Immunol., Stanford Univ. Sch. Med., Stanford, CA,  
94305-5402, USA  
SO International Immunology (1998), 10(6), 727-741  
PB CODEN: INIMEN, ISSN: 0953-8178  
DT Oxford University Press  
LA English  
RE.CNT 13  
THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 43 OF 43 MEDLINE DUPLICATE 6  
AN 97075125 PubMed ID: 8917551  
DN 97075125  
TI Disrupted splenic architecture, but normal lymph node development in mice  
expressing a soluble lymphotoxin-beta receptor  
-J6g1 fusion protein.  
AU Ettinger R, Browning J L, Michie S A, van Ewijk W, McDevitt H O  
CS Department of Microbiology and Immunology, Stanford University School of  
Medicine, CA 94305, USA.  
NC AI-36535 (NIAID)  
CA-48734 (NCI)  
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF  
AMERICA. (1996 Nov 12) 93 (23) 13102-7.  
Journal code: 7505876. ISSN: 0027-8424.  
CY United States  
LA English  
TI Journal: Article: (JOURNAL ARTICLE)  
FS Priority Journals  
EM 199612  
ED Entered STN: 19970128  
Last Updated on STN: 19970128  
Entered Medline: 19961230

=> d his

(FILE 'HOME' ENTERED AT 12:32:53 ON 11 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, EMBASE, CAPLUS, USPATFULL',  
ENTERED AT 12:33:20 ON 11 FEB 2003  
L1 136 S LYMPHOTOXIN (A) BETA (A) RECEPTOR AND ANTIBODY  
L2 42 S L1 AND INTERFERON  
L3 34 DUP REM L2 (8 DUPLICATES REMOVED)  
L4 541 S LYMPHOTOXIN (A) BETA (A) RECEPTOR  
L5 66 S L4 AND PROMOT  
L6 43 DUP REM L5 (23 DUPLICATES REMOVED)

=> b 14 and cancer  
48 L4 AND CANCER

=> dup rem 17  
PROCESSING COMPLETED FOR L7  
L8 39 DUP REM L7 (9 DUPLICATES REMOVED)

=> d 1-39

L8 ANSWER 1 OF 39 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1  
AN 2002:409195 CAPLUS  
DN 137:1567  
TI Human apoptosis inducing molecule II and its cDNA and use thereof in drug  
screening and therapy  
IN Ebner, Reinhard; Yu, Guo-Jiang; Ruben, Steven M.; Ullrich, Stephen  
PA Human Genome Sciences, Inc., USA  
SO U.S. Pat. Appl. Publ., 79 pp., Cont.-in-part of U.S. Ser. No. 822,953,  
abandoned.  
DT Patent  
LA English  
FAN.CNT 5  
PATENT NO. KIND DATE APPLICATION NO. DATE

PI US 2002064869 A1 20020530 US 1998-27287 19980220  
US 6479254 B2 20021112 CA 1999-231057 19990107  
CA 2317057 AA 19990715 WO 1999-US242 19990107  
WO 9935262 A2 19990715  
WO 9935262 A3 19991202

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,  
DK, EE, ES, FI, GB, GD, GE, GR, GU, HK, IL, IN, IS, JP,  
KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN,  
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, BG, BR, BU, CF, CG, CI,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
CM, GA, GN, GM, ML, MR, NE, SN, TD, TG  
AU 9921063 A1 19990726 AU 1999-21063 19990107  
EP 1044270 A2 20001018 EP 1999-901341 19990107  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

JP 200250043 T2 20020108 JP 2000-527646 19990107  
CA 2321186 AA 19990826 CA 1999-2321186 19990219  
WO 9942584 A1 19990826 WO 1999-US3703 19990219  
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,  
DK, EE, ES, FI, GB, GD, GE, GR, GU, HK, IL, IN, IS, JP,  
KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN,  
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, BG, BR, BU, CF, CG, CI,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
CM, GA, GN, GM, ML, MR, NE, SN, TD, TG  
AU 9929721 A1 19990906 AU 1999-29721 19990219  
EP 1054968 A1 20001129 EP 1999-910370 19990219  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

JP 200250433 T2 20020212 JP 2000-532524 19990219  
US 2002081647 A1 20020627 US 1999-25256 19990219  
US 6495520 B2 20021217  
US 1996-13923P P 19960322  
PRAI US 1996-30157P B2 19961031  
US 1997-822953 A 19970321  
US 1998-3886 A 19980107  
US 1998-27287 A 19980220  
US 1998-75403P P 19980220  
WO 1999-US242 W 19990107  
WO 1999-US3703 W 19990219

L8 ANSWER 2 OF 39 CAPLUS COPYRIGHT 2003 ACS  
AN 2002:555371 CAPLUS  
DN 137:139348  
TI Molecular antigen array for vaccines against infectious disease.

cancer, allergies and autoimmune diseases  
 IN Maurer, Patrick; Lechner, Franziska; Ortman, Rainer; Luegend, Rainer;  
 PA Staendliel, Matthias; Frey, Peter; Renner, Wolfgang A.; Bachmann, Martin;  
 SO Tisoc, Alain; Seibel, Peter; Piossek, Christine  
 PA Cyto Biotechnology A.-G., Switzerland; Novartis Pharma A.-G.  
 PCT Int. Appl., 418 pp.  
 DT Patent  
 LA English  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002056907	A2	20020725	WO 2002-1B16	20020121
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TW, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			

US 2001-263799 P 20010504  
 US 2001-326988 P 20011005  
 US 2001-310458 P 20011107

ANSWER 3 OF 39 CAPLUS COPYRIGHT 2003 ACS

IN 137:124189  
 TI Vaccine compositions comprising molecular antigen array against  
 cancer, infection, and allergy  
 IN Renner, Wolfgang A.; Bachmann, Martin; Tisoc, Alain; Maurer, Patrick;  
 PA Lechner, Franziska; Seibel, Peter; Piossek, Christine  
 PA Cyto Biotechnology A.-G., Switzerland  
 PCT Int. Appl., 442 pp.  
 DT Patent  
 LA English  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002056905	A2	20020725	WO 2002-1B16	20020121
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TW, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			

US 2001-263799 P 20010504  
 US 2001-326988 P 20011005  
 US 2001-310458 P 20011107

ANSWER 4 OF 39 CAPLUS COPYRIGHT 2003 ACS

IN 136:124074  
 TI Humanized anti-lymphotoxin beta receptor  
 (LT-beta-R) antibodies for treating tumor

Garber, Ellen; Lyne, Paul; Saldanha, Jose W.  
 IN Biogen, Inc., USA  
 PA PCT Int. Appl., 41 pp.  
 SO CODEN: PIXKD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030986	A2	20020418	WO 2001-US32140	20011012
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TW, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			

US 2000-240285 P 20010113  
 US 2001-275289 P 20010313  
 US 2001-299987 P 20010621  
 WO 2001-US32140 W 20011012

ANSWER 5 OF 39 USPTAFULL

IN 2002:272856 USPTAFULL  
 TI TNF receptor-like molecules and uses thereof  
 IN Theill, Lars Eyde, Thousand Oaks, CA, UNITED STATES  
 Yeh, Richard, Ithaca, NY, UNITED STATES  
 Silbiger, Scott Michael, Woodland Hills, CA, UNITED STATES  
 Yu, Gang, Thousand Oaks, CA, UNITED STATES  
 Senaldi, Giorgio, Thousand Oaks, CA, UNITED STATES  
 AI US 2001-946018 A1 20020107  
 PRAI US 2000-230191P 20000905 (60)

DT Utility  
 FS APPLICATION  
 IN.CNT 5781  
 INCL INCLM: 435/069.100  
 INCLM: 435/325.000; 435/320.100; 530/350.000; 536/023.500; 435/194.000  
 NCLM: 435/069.100  
 NCLM: 435/325.000; 435/320.100; 530/350.000; 536/023.500; 435/194.000  
 IC [7]  
 ICM: C12P021-02  
 ICS: C12N005-06; C07H021-04; C12N009-12  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 6 OF 39 USPTAFULL

IN 2002:272468 USPTAFULL  
 TI Tumor necrosis factor receptors galpha & gbeta  
 IN Gentz, Reinert L., Rockville, MD, UNITED STATES  
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
 Yu, Guoliang, Berkeley, CA, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Ni, Jian, Germantown, MD, UNITED STATES  
 Feng, Ping, Gaithersburg, MD, UNITED STATES  
 Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)  
 AI US 2001-935727 A1 20020107  
 US 2001-935727 A1 20010824 (9)  
 PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998,  
 2000, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar  
 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13  
 Jan 1998, PENDING

PRAI US 2001-303224P 20010706 (60)  
US 2000-252131P 20001121 (60)  
US 2000-227598P 20000825 (60)  
US 1999-168235P 19991201 (60)  
US 1999-146371P 19990802 (60)  
US 1999-131964P 19990430 (60)  
US 1999-131270P 19990427 (60)  
US 1999-124092P 19990312 (60)  
US 1999-121774P 19990304 (60)  
US 1997-35496P 19970114 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 12989  
INCL INCLM: 424/178.100  
INCL INCLS: 530/389.100  
NCLM: 424/178.100  
NCLS: 530/389.100  
IC [7]  
ICM: A61K039-395  
ICS: C07K016-46

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 39 USPTAFULL  
AN 2002:259408 USPTAFULL  
TI Gene expression profiles in liver cancer  
IN Horne, Barci T.; Galtersburg, MD, UNITED STATES  
Scherf, Uwe, Galtersburg, MD, UNITED STATES  
Vockley, Joseph, Damascus, MD, UNITED STATES  
PI US 2002:42381 AI 20021003  
AI US 2001-880107 AI 20010614 (9)  
PRAI US 2000-211379P 20000614 (60)  
US 2000-237054P 20001002 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 15937  
INCL INCLM: 514/044.000  
INCL INCLS: 435/006.000  
NCLM: 514/044.000  
NCLS: 435/006.000  
IC [7]  
ICM: A61K048-00  
ICS: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 39 USPTAFULL  
AN 2002:235448 USPTAFULL  
TI Human tumor necrosis factor receptor-like protein 8  
IN Ni, Jian, Rockville, MD, UNITED STATES  
Moore, Paul A., Germantown, MD, UNITED STATES  
PI US 2002:237637 AI 20020912  
AI US 2001-768779 AI 20010125 (9)  
PRAI Continuation of Ser. No. US 1998-86582, filed on 29 May 1998, ABANDONED  
US 1997-48020P 19970529 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3860  
INCL INCLM: 435/069.100  
INCL INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
NCLM: 435/069.100  
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
IC [7]  
ICM: C07K014-715  
ICS: C12P021-02; C12N005-06; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 39 USPTAFULL  
AN 2002:235426 USPTAFULL  
TI TRAF-3 deletion isoforms and uses thereof  
IN Lederman, Seth, New York, NY, UNITED STATES  
Byrdhovan, Minfried Van, Bellingham, WA, UNITED STATES  
PI US 2002:212615 AI 20020912  
AI US 2001-950902 AI 20010910 (9)  
PRAI Continuation of Ser. No. WO 2000-US6503, filed on 10 Mar 2000, UNKNOWN  
Continuation-in-part of Ser. No. US 1999-268544, filed on 11 Mar 1999,  
PENDING  
DT Utility  
FS APPLICATION  
LN.CNT 4140  
INCL INCLM: 435/007.210  
INCL INCLS: 435/183.000; 435/325.000; 435/320.100; 530/350.000; 536/023.200  
NCLM: 435/007.210  
NCLS: 435/183.000; 435/325.000; 435/320.100; 530/350.000; 536/023.200  
IC [7]  
ICM: G01N033-567  
ICS: C07H021-04; C12N009-00; C07K014-705

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 39 USPTAFULL  
AN 2002:228312 USPTAFULL  
TI Treatment of autoimmune disease  
IN Faustman, Denise, Weston, MA, UNITED STATES  
PI US 2002:23472 AI 20020905  
AI US 2001-768769 AI 20010123 (9)  
PRAI Continuation-in-part of Ser. No. US 2000-521064, filed on 8 Mar 2000,  
ABANDONED  
US 1999-123738P 19990310 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1830  
INCL INCLM: 514/044.000  
INCL INCLS: 435/005.000; 435/235.100; 435/325.000; 435/007.920; 435/069.500  
NCLM: 514/044.000  
NCLS: 435/005.000; 435/235.100; 435/325.000; 435/007.920; 435/069.500  
IC [7]  
ICM: C12Q001-70  
ICS: G01N033-53; G01N033-543; A61K031-70; A01N043-04;  
C12P021-02; C12N007-00; C12N007-01; C12N005-00; C12N005-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 39 USPTAFULL  
AN 2002:206139 USPTAFULL  
TI Compositions and methods for the therapy and diagnosis of colon  
IN cancer  
Pyle, Ruth A., Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Secrett, Heather, Seattle, WA, UNITED STATES  
PA Corix Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)  
PI US 2002:210832 AI 20020815  
AI US 2001-919580 AI 20010710 (9)  
PRAI US 2001-302702P 20010703 (60)  
US 2001-277495P 20010320 (60)  
US 2000-237406P 20001002 (60)  
US 2000-223265P 20000803 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 5425  
INCL INCLM: 435/007.100  
INCL INCLS: 536/023.100; 530/350.000  
NCLM: 435/007.100  
NCLS: 536/023.100; 530/350.000

IC [7]  
ICM: G01N033-53  
ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 39 USPTAFULL  
AN 2002:171619 USPTAFULL  
TI Anti-lymphotoxin-beta receptor antibodies  
IN as anti-tumor agents  
Browning, Jeffrey L., Brookline, MA, UNITED STATES  
Meier, Werner, Burlington, MA, UNITED STATES  
Benjamin, Christopher D., Beverly, MA, UNITED STATES  
PI US 2002090366 A1 20020711  
AI US 2001-931602 A1 20010816 (9)  
RLI Division of Ser. No. US 1998-87560, filed on 5 Jun 1998, PATENTED A 371 of International Ser. No. WO 1996-051386, filed on 26 Jan 1996, UNKNOWN Continuation-in-part of Ser. No. US 1995-378968, filed on 26 Jan 1995, PENDING

DT Utility  
FS APPLICATION  
LN.CNT 1764  
INCL INCLM: 424/094.100  
NCL INCLS: 424/178.100  
NCLM: 424/094.100  
NCLS: 424/178.100  
IC [7]  
ICM: A61K039-395  
ICS: A61K039-40  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 39 USPTAFULL  
AN 2002:157048 USPTAFULL  
TI APOPTOSIS INDUCING MOLECULE II AND METHODS OF USE  
IN EBNER, REINHARD, GAITHERSBURG, MD, UNITED STATES  
YU, GUO-LIANG, BERKELEY, CA, UNITED STATES  
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES  
ZHANG, JUN, BETHESDA, MD, UNITED STATES  
ULRICH, STEPHEN, ROCKVILLE, MD, UNITED STATES  
ZHAH, YIFAN, GAITHERSBURG, MD, UNITED STATES  
PA Human Genome Sciences (U.S. Corporation)  
PI US 2002081647 A1 20020627  
AI US 6495520 B2 20021217  
US 1999-252656 A1 19990219 (9)  
AI Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998, PENDING Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-822953, filed on 21 Mar 1997, ABANDONED  
PRAI US 1998-75409P 19980220 (60)  
US 1996-13923P 19960322 (60)  
US 1996-30157P 19961031 (60)

DT Utility  
FS APPLICATION  
LN.CNT 6195  
INCL INCLM: 435/069.100  
NCL INCLS: 530/350.000; 530/399.000; 514/012.000; 536/023.500  
NCLM: 514/012.000  
NCLS: 530/300.000; 530/324.000; 530/350.000  
IC [7]  
ICM: A61K038-18  
ICS: C12P021-06; C07H021-04; C07K014-00; G01N033-53  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 39 USPTAFULL  
AN 2002:119846 USPTAFULL  
TI Human G-protein Chemokine receptor (CCR5) HDGMR10

IN Rosen, Craig A., Laytonville, MD, UNITED STATES  
Roschke, Viktor, Rockville, MD, UNITED STATES  
Li, Yi, Sunnyvale, CA, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
PI US 2002061834 A1 20020523  
AI US 2001-779880 A1 20010209 (9)  
PRAI US 2000-181258P 20000209 (60)  
US 2000-187999P 20000309 (60)  
US 2000-234336P 20000922 (60)

DT Utility  
FS APPLICATION  
LN.CNT 18667  
INCL INCLM: 514/001.000  
NCL INCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100  
NCLM: 514/001.000  
NCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100  
IC [7]  
ICM: A61K031-00  
ICS: C07H021-04; C07K014-705; C12N005-06; C12P021-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 39 USPTAFULL  
AN 2002:92268 USPTAFULL  
TI Human G-protein Chemokine Receptor HDGMR10  
IN Rosen, Craig A., Laytonville, MD, UNITED STATES  
Roschke, Viktor, Rockville, MD, UNITED STATES  
Li, Yi, Sunnyvale, CA, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
PI US 2002048786 A1 20020425  
AI US 2001-779879 A1 20010209 (9)  
PRAI US 2000-181258P 20000209 (60)  
US 2000-187999P 20000309 (60)  
US 2000-234336P 20000922 (60)

DT Utility  
FS APPLICATION  
LN.CNT 17969  
INCL INCLM: 435/069.100  
NCL INCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000  
NCLM: 435/069.100  
NCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000  
IC [7]  
ICM: G01N033-53  
ICS: G01N033-567; A61K038-00; C07H021-04; C12P021-06; A61K039-395; C12N005-02; C12N005-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 39 USPTAFULL  
AN 2002:72443 USPTAFULL  
TI Method for the high level expression of active lymphotoxin-beta receptor immunoglobulin chimeric proteins and their purification  
IN Browning, Jeffrey, Brookline, MA, UNITED STATES  
Meier, Werner, Burlington, MA, UNITED STATES  
Meier, Werner, Konrad, North Reading, MA, UNITED STATES  
PI US 2002039580 A1 20020404  
AI US 2001-767370 A1 20010123 (9)  
RLI Continuation of Ser. No. WO 1999-0529873, filed on 16 Dec 1999, UNKNOWN  
PRAI US 1998-112752P 19981217 (60)

DT Utility  
FS APPLICATION  
LN.CNT 1163  
INCL INCLM: 424/178.100  
NCL INCLS: 530/389.100; 435/069.700; 435/328.000; 530/351.000  
NCLM: 424/178.100  
NCLS: 530/389.100; 435/069.700; 435/328.000; 530/351.000

IC [7]  
ICM: A61K039-395  
ICS: C12P021-04; C07K016-46  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 39 USPATFILL  
AN 2002:22092 USPATFILL  
TI Nucleic acid sequences associated with aging, particularly skin aging  
IN Brown, Glenn C., Seattle, WA, UNITED STATES  
Brown, Joseph P., Seattle, WA, UNITED STATES  
Pritchard, David, Seattle, WA, UNITED STATES  
PI US 2002012927 A1 20020131  
PRAI US 2001-802718 A1 20010308 (9)  
PRAI US 2000-188584P 20000310 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2368  
INCL INCLM: 435/006.000  
INCL INCLS: 435/007.210  
NCL NCLM: 435/006.000  
NCL NCLS: 435/007.210  
IC [7]  
ICM: C12N001-68  
ICS: G01N033-567; A61K031-665  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 39 USPATFILL  
AN 2002:8587 USPATFILL  
TI Multivalent antibodies and uses therefor  
IN Miller, Kathy L., San Francisco, CA, UNITED STATES  
Presta, Leonard G., San Francisco, CA, UNITED STATES  
GENENTECH, INC. (U.S. corporation)  
PI US 2002004587 A1 20020110  
AI US 2001-813341 A1 20010320 (9)  
PRAI US 2000-195819P 20000411 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4913  
INCL INCLM: 530/388.800  
INCL INCLS: 536/023.500; 435/325.000; 435/334.000; 424/143.100  
NCL NCLM: 530/388.800  
NCL NCLS: 536/023.500; 435/325.000; 435/334.000; 424/143.100  
IC [7]  
ICM: C07K036-28  
ICS: A61K039-395; C07H021-04; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 39 USPATFILL  
AN 2002:188392 USPATFILL  
TI TRAF family molecules, polynucleotides encoding them, and antibodies  
IN against them  
Nakata, Motomi, Yokohama, JAPAN  
Nakano, Hiroyasu, Tokyo, JAPAN  
Yagita, Hideo, Tokyo, JAPAN  
Okumura, Ko, 9-2-610, Azusawa 3-chome, Itabashi-ku, Tokyo 174-0051, JAPAN  
PA Okumura, Ko, Tokyo, JAPAN (non-U.S. individual)  
PI US 6426403 B1 20020730  
AI US 1998-138277 19980818 (9)  
RLI Continuation-in-part of Ser. No. WO 1997-JP512, filed on 24 Feb 1997  
PRAI JP 1996-14674 19960222  
DT Utility  
FS GRANTED  
LN.CNT 1694  
INCL INCLM: 530/350.000

NCL INCLS: 530/351.000; 435/069.100; 536/023.100  
NCL NCLM: 530/350.000  
NCL NCLS: 435/069.100; 530/351.000; 536/023.100  
IC [7]  
ICM: C07K014-52  
ICS: C07H021-04; C12N015-00  
EXF 530/300; 530/350; 530/351; 435/183; 435/174; 435/69.1; 536/23.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 39 USPATFILL  
AN 2002:152777 USPATFILL  
TI Nucleic acid encoding a TRAF-3 deletion isoform  
IN Lederman, Seth, New York, NY, United States  
Van Eyndhoven, Winfried, Bayside, NY, United States  
The Trustees of the University in the City of New York, New York, NY.  
PA United States (U.S. corporation)  
PI US 6410710 B1 20020625  
AI US 1999-268544 19990311 (9)  
DT Utility  
FS GRANTED  
LN.CNT 3011  
INCL INCLM: 536/023.500  
INCL INCLS: 536/023.100; 435/320.100  
NCL NCLM: 536/023.500  
NCL NCLS: 435/320.100; 536/023.100  
IC [7]  
ICM: C07H021-04  
ICS: C12N015-11; C12N015-63  
EXF 536/23.1; 536/23.5; 435/320.1; 424/93.1; 514/44  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 39 USPATFILL  
AN 2002:136562 USPATFILL  
TI Soluble lymphotoxin-beta receptors as  
IN therapeutic agents for the treatment of immunological disease  
Browning, Jeffrey U., Brookline, MA, United States  
Benjamin, Christopher D., Beverly, MA, United States  
Hochman, Paula S., Newton, MA, United States  
BioGen, Inc., Cambridge, MA, United States (U.S. corporation)  
PI US 6463087 B1 20020611  
AI WO 9703687 19970206  
WO 1998-166 19980608 (9)  
WO 1996-US12010 19960719  
RLI Continuation-in-part of Ser. No. US 1995-505606, filed on 21 Jul 1995.  
DT now patented, Pat. No. US 5925351  
FS Utility  
LN.CNT 1983  
INCL INCLM: 424/134.100  
INCL INCLS: 424/134.100; 424/133.100; 514/002.000; 514/008.000; 530/387.100; 530/387.300  
NCL NCLM: 424/134.100  
NCL NCLS: 424/133.100; 514/002.000; 514/008.000; 530/387.100; 530/387.300  
IC [7]  
ICM: A61K039-395  
EXF 424/148.1; 424/144.1; 424/145.1; 424/156.1; 514/2; 514/8; 530/395; 530/387.1; 530/388.22; 530/388.23; 530/388.73; 530/388.85; 530/389.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 39 USPATFILL  
AN 2002:129717 USPATFILL  
TI Antisense modulation of expression of tumor necrosis factor  
receptor-associated factors (TRAFs)

IN Baker, Brenda F., Carlsbad, CA, United States  
 Comert, Bret M., Carlsbad, CA, United States  
 Monta, Brett P., La Costa, CA, United States  
 Xu, Xoxing S., Madsen, NJ, United States  
 PA ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S.  
 Corporation)  
 PI US 6399297 B1 20020604  
 AI US 1998-167109 19981006 (9)  
 DT Utility  
 FS GRANTED  
 INCL INCLM: 435/006.000  
 INCLM: 435/091.100; 435/375.000; 536/023.100; 536/024.500  
 NCLM: 435/006.000  
 NCLM: 435/091.100; 435/375.000; 536/023.100; 536/024.500  
 IC [71]  
 ICM: C07H021-04  
 ICS: C120001-68; C12N015-63  
 514/44; 536/23.1; 536/24.3; 536/24.5; 435/6; 435/91.1; 435/325; 435/366;  
 435/375  
 EXF 435/375  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 39 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
 AN 2002264120 EMBASE  
 TI Lymphotoxin- $\beta$  receptor immune  
 AU interaction promotes tumor growth by inducing angiogenesis.  
 Heindrich I.; Stoelcker B.; Stopfer P.; Muller P.; Cernatani G.; Guba M.;  
 Steinhauser M.; Nedospasov S.A.; Pfeiffer K.; Mannel D.N.  
 D.N. Mannel, Department of Pathology, University of Regensburg,  
 F.-J.-Strauss-Allee 11, D-93042 Regensburg, Germany.  
 Daniela.maenele@klinik.uni-regensburg.de  
 Cancer Research, (15 Jul 2002) 62/14 (4034-4040).  
 SO Refs: 35  
 ISSN: 0008-5472 CODEN: CREAB8  
 CY United States  
 DT Journal Article  
 FS 016 Cancer  
 026 Immunology, Serology and Transplantation  
 LA English  
 SL English

L8 ANSWER 24 OF 39 CAPLUS COPYRIGHT 2003 ACS  
 AN 2001.338564 CAPLUS  
 DN 134:348630  
 TI New members of the TRAF (tumor necrosis factor receptor-associated factor)  
 protein family with possible therapeutic uses  
 IN Zapata, Juan M.; Reed, John C.  
 PA The Burnham Institute, USA  
 SO PCT Int. Appl., 156 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032696	A2	20010510	WO 2000-US30533	20001103
WO 2001032696	A3	20020117		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DR, DK, DK, DE, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, KZ, LG, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, SV, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, CH, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AT, BE, CH, CY,				

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG  
 EP 1228088  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AU, TR  
 PRAI US 1999-434784 A2 19991105  
 WO 2000-US30533 W 20001103

L8 ANSWER 25 OF 39 USPATFILL  
 AN 2001.231143 USPATFILL  
 TI Arrays for identifying agents which mimic or inhibit the activity of  
 interferons  
 IN Silverman, Robert H., Beachwood, OH, United States  
 Williams, Bryan R. G., Cleveland, OH, United States  
 Der, Sandy, Cleveland, OH, United States  
 The Cleveland Clinic Foundation, Cleveland, OH, United States (U.S.  
 Corporation)  
 PI US 631396 B1 20011218  
 AI US 1999-405438 19990923 (9)  
 PRAI US 1998-101497P 19980923 (60)  
 DT Utility  
 FS GRANTED  
 INCL INCLM: 435/006.000  
 INCLM: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310  
 NCLM: 435/006.000  
 NCLM: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310  
 IC [71]  
 ICM: C120001-68  
 ICS: C120001-36; C07H021-04  
 435/6; 435/287.2; 536/23.1; 536/24.31; 536/23.52  
 EXF 435/6  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 26 OF 39 USPATFILL  
 AN 2001.196600 USPATFILL  
 TI Lymphotoxin- $\alpha$ - $\beta$  complexes and anti-lymphotoxin- $\beta$  receptor  
 antibodies as anti-tumor agents  
 IN Browning, Jeffrey L., 32 Milton Rd., Brookline, MA, United States 02146  
 Meier, Werner, 31 Bedford St., Burlington, MA, United States 01803  
 Benjamin, Christopher D., 2 Oak Hill La., Beverly, MA, United States  
 01915  
 PI US 6312691 B1 20011106  
 AI US 1998-875560 19980605 (8)  
 WO 1996-US1386 19980605 PCT 371 date  
 19980605 PCT 102(e) date

DT	Utility
FS	GRANTED
INCL	2254
INCLM: 424/143.100	
INCLM: 424/144.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;	
530/388.750; 530/388.800; 530/388.850	
NCLM: 424/143.100	
NCLM: 424/144.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;	
530/388.750; 530/388.800; 530/388.850	
IC [71]	
ICM: A61K039-395	
424/130.1; 424/143.1; 424/144.1; 424/809; 530/388.22; 530/388.7;	
530/388.75; 530/388.8; 530/388.85	
EXF 530/388.75	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L8 ANSWER 27 OF 39 USPATFILL  
 AN 2001.75530 USPATFILL  
 TI Fas ligand-like protein, its production and use

IN Mishi, Kazunori, Ibaraki, Japan  
 Hikiuchi, Yukiko, Ibaraki, Japan  
 PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)  
 PI WO 625878 19980123 20010522  
 WO 980368 19980123 19970904 (8)  
 US 1997-913014 19970717  
 WO 1997-UP2480 19970904 PCT 371 date  
 19970904  
 PRAI JP 1996-191204 19960719 PCT 102(e) date  
 JP 1996-211695 19960809  
 JP 1997-19330 19970131  
 DT Utility  
 FS Granted  
 LN.CNT 4854  
 INCL INCLM: 530/350.000  
 NCL NCLM: 530/350.000  
 IC [7]  
 ICM: C07K001-00  
 EXP 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 28 OF 39 USPTFULL  
 L8 2001:44016 USPTFULL  
 TI Proteins capable of regulating NF-kappa.B JNK and apoptosis pathways  
 IN and methods of using the same  
 Chaudhary, Preet M., Dallas, TX, United States  
 Hood, Leroy, Seattle, WA, United States  
 PA University of Washington/Stowers Institute for Medical Research, United  
 States (U.S. corporation)  
 PI US 6207458 20010327  
 AI US 1998-74044 19980507 (9)  
 DT Utility  
 FS Granted  
 LN.CNT 1982  
 INCL INCLM: 435/503.000  
 INCLM: 435/004.000; 435/007.100; 435/007.720; 435/018.000; 435/023.000;  
 NCL 435/040.500; 435/040.510; 435/040.520  
 NCLM: 435/006.000  
 NCLM: 435/004.000; 435/007.100; 435/007.720; 435/018.000; 435/023.000;  
 IC 435/040.500; 435/040.510; 435/040.520  
 [7]  
 ICM: C12Q001-37  
 ICS: C12Q001-00; G01N033-567; G01N033-18; G01N033-53  
 EXP 435/503; 435/4; 435/7.1; 435/7.72; 435/18; 435/23; 435/40.5; 435/40.51;  
 435/40.52  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 29 OF 39 CAPLUS COPYRIGHT 2003 ACS  
 L8 2001:544229 CAPLUS  
 DN 135:313303  
 TI Pharmacogenomic dissection of resistance to thymidylate synthase  
 inhibitors  
 Wang, Weiguang; Marsh, Sharon; Casady, James; McLeod, Howard L.  
 AU Department of Medicine and Therapeutics, Institute of Medical Sciences,  
 CS University of Aberdeen, Aberdeen, AB25 2ZD, UK  
 SO Cancer Research (2001) 6(14): 5505-5510  
 CODEN: CREAB; ISSN: 0008-5472  
 PB American Association for Cancer Research  
 DT Journal  
 LA English  
 RE.CNT 21  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 30 OF 39 USPTFULL  
 L8 2000:168142 USPTFULL  
 AN Proteins capable of regulating NF-kappa.B JNK and apoptosis pathways  
 TI and methods of using the same  
 IN Chaudhary, Preet M., Dallas, TX, United States  
 PA Hood, Leroy, Seattle, WA, United States  
 University of Washington, Seattle, WA, United States (U.S. corporation)  
 Stowers Institute for Medical Research, Kansas City, MO, United States  
 PI US 6160095 20001212  
 AI US 1999-382155 19990824 (9)  
 PRAI Division of Ser. No. US 1998-74044, filed on 7 May 1998  
 DT Utility  
 FS Granted  
 LN.CNT 2638  
 INCL INCLM: 530/350.000  
 NCL NCLM: 530/350.000  
 IC [7]  
 ICM: C07K014-435  
 ICS: C07K014-47  
 EXP 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 31 OF 39 USPTFULL  
 L8 2000:146513 USPTFULL  
 AN Ligand for herpes simplex virus entry mediator and methods of use  
 TI Ware, Carl E., Solana Beach, CA, United States  
 IN La Jolla Institute for Allergy and Immunology, La Jolla, CA, United  
 States (U.S. corporation)  
 PI US 6140467 20001031  
 AI US 1997-898234 19970730 (8)  
 PRAI US 1997-51964P 19970707 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 1522  
 INCL INCLM: 530/350.000  
 NCL NCLM: 530/350.000  
 IC [7]  
 ICM: C07K014-47  
 EXP 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 32 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
 L8 2000:345160 BIOSIS  
 AN The lymphotoxin-beta receptor is necessary  
 DN and sufficient for LIGHT-mediated apoptosis of tumor cells.  
 TI Rooney, Isabelle A.; Butrovich, Kris D.; Glass, Alison A.; Borboroglu,  
 AU Stephen; Benedict, Chris A.; Whitbeck, J. Charles; Cohen, Gary H.;  
 Eisenberg, Roselyn J.; Ware, Carl F. (1)  
 CS (1) Division of Molecular Immunology, La Jolla Institute for Allergy and  
 SO Immunology, 10355 Science Center Dr., San Diego, CA, 92121 USA  
 14307-14315 print.  
 ISSN: 0021-9258.  
 DT Article  
 LA English  
 SL English

ANSWER 33 OF 39 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
 L8 2000237999 EMBASE  
 AN Molecular cloning and characterization of a mouse homolog of human  
 TI TNFSF14, a member of the TNF superfamily.  
 AU Misaawa K.; Nosaka T.; Kojima T.; Hirai M.; Kitamura T.  
 Dr. T. Kitamura, Department of Hematopoietic Factors, Institute of Medical

Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. kltamura@ims.u-tokyo.ac.jp  
Cytogenetics and Cell Genetics, (2000) 89/1-2 (89-91).  
Refs: 14  
ISSN: 0301-0171 CODEN: CGCGBR

DT Swiss Patent  
DT Journal: Article  
FS 022 Human Genetics  
LA English  
SL English

LA ANSWER 34 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
DN 2000.385559 BIOSIS  
AN PREV200000385559  
TI Activation of the lymphotoxin beta receptor  
as a cancer therapy.  
Browning, Jeffrey (1); Mackay, Fabienne (1); Wilson, Cheryl (1)  
(1) Department of Immunology, Inflammation and Cell Biology, Biogen, Cambridge, CA USA

SO Scandinavian Journal of Immunology, (June, 2000) Vol. 51, No. Supplement 1, pp. 34. print.  
Meeting Info.: 8th International TNF Congress, Conference on Tumor Necrosis Factor and Related Molecules Scientific Advances and Medical Applications Trondheim, Norway May 14-18, 2000  
ISSN: 0300-9475.

DT Conference  
LA English  
SL English

LA ANSWER 35 OF 39 CAPLUS COPYRIGHT 2003 ACS  
AN 1999.549380 CAPLUS  
DN 131.180813  
TI Apoptosis-inducing molecule II, its encoding cDNA sequence, and therapeutic and clinical uses  
Ehner, Reinhard; Xu, Guo-liang; Ruben, Steven M.; Zhang, Jun; Ullrich, Stephen; Zhai, Yifen  
Human Genome Sciences, Inc., USA  
PCT Int. Appl., 224 pp.  
CODEN: PIXXD2  
LA English  
FAN.CNT 5

PATENT NO.

PI WO 9442584

AL 19990826

NO 1999-US3703

19990219

W: AL, AM, AT, AU, AZ, BA, BB, BC, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RM: GH, GM, KE, LS, MM, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CA, CN, GM, ML, MR, NE, SN, TD, TG

US 2002064669

AL 20020531

US 1998-27287

19980220

US 6479254

B2 20021112

CA 1999-2321186

19990219

CA 2321186

AA 19990826

AU 1999-28721

19990219

AU 9929721

EP 1054968

EP 1999-910970

19990219

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

JP 200204333

T2 20020212

JP 2000-53254

19990219

PRAI US 1998-27287

A 19980220

US 1998-75409P

P 19980220

US 1996-13923P

P 19960322

US 1996-30157P P 19961031  
US 1997-822953 B2 19970321  
US 1999-US3703 W 19990219  
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LA ANSWER 36 OF 39 CAPLUS COPYRIGHT 2003 ACS  
AN 1999.451368 CAPLUS  
DN 131.186868

TI Cloning and cDNA sequence encoding human apoptosis-inducing molecule II  
Ehner, Reinhard; Ruben, Steven M.; Xu, Guo-liang; Ullrich, Stephen  
Human Genome Sciences, Inc., USA  
PCT Int. Appl., 165 pp.  
CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 5

PATENT NO.

PI WO 9935262

A2 19990715

MO 1999-US242

19990107

W: AL, AM, AT, AU, AZ, BA, BB, BC, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RM: GH, GM, KE, LS, MM, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CA, CN, GM, ML, MR, NE, SN, TD, TG

US 2002064669

AL 20020530

US 1998-27287

19980220

US 6479254

B2 20021112

CA 1999-2317057

19990107

CA 2317057

AA 19990715

AU 1999-21063

19990107

AU 9921063

EP 1044270

EP 1999-901341

19990107

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

JP 2002500043

T2 20020108

JP 2000-527646

19990107

PRAI US 1998-3886

A 19980107

US 1998-27287

A 19980220

US 1996-13923P

P 19960322

US 1996-30157P

P 19961031

US 1997-822953

B2 19970321

US 1999-US242

W 19990107

LA ANSWER 37 OF 39

LA 1998289299

MEDLINE

DUPLICATE 2

AN 1998289299

Pubmed ID: 9626059

98289299

TI TRAF-4 expression in epithelial progenitor cells. Analysis in normal adult, fetal, and tumor tissues.

Comment in: Am J Pathol. 1998 Dec;153(6):2007-8

Krajewska M; Krajewski S; Zapata J M; Van Arsdale T; Gascoyne R D; Berern K; McEadden D; Shabak A; Hugh J; Reynolds A; Clevenger C V; Reed J C

Burnham Institute, La Jolla, CA 92037, USA.

CA-69381 (NCTI)

AMERICAN JOURNAL OF PATHOLOGY, (1998 Jun) 152 (6) 1549-61.

Journal code: 0370502. ISSN: 0002-9440.

United States

DT Journal: Article: (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 199807

Entered STM: 19980716

Last Updated on STM: 20000303

Entered Medline: 19980707



L8 ANSWER 38 OF 39 MEDLINE  
AN 1998411370 MEDLINE  
DN 98411370 PubMed ID: 9739048  
TI LIGHT, a novel ligand for lymphotoxin beta  
receptor and TR2/HVEM induces apoptosis and suppresses in vivo  
tumor formation via gene transfer.  
AU Zhai Y; Guo R; Hsu T L; Yu G L; Ni J; Kwon B S; Jiang G W; Lu J; Tan J;  
Ungurus M; Carter K; Rojas L; Zhu F; Lincoln C; Endress G; Xing L; Wang S;  
Oh K O; Gentz R; Ruben S; Lippman M E; Hsieh S L; Yang D  
NC Human Genome Sciences, Inc., Rockville, Maryland 20850, USA.  
CA51008 (NCI)  
SO JOURNAL OF CLINICAL INVESTIGATION, (1998 Sep 15) 102 (6) 1142-51.  
JOURNAL code: 7802877. ISSN: 0021-9738.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
ED Entered STN: 19981021  
Last updated on STN: 19981021  
Entered Medline: 19981013

L8 ANSWER 39 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 1996:351516 BIOSIS  
DN PREVI19969073872  
TI LT-beta-R interacts with multiple TRAFs: signaling specificity in the  
activation of NF-kappa-B.  
AU Force, Walker R. (1); Williams-Abbott, Laura (1); Mostalos, George; Keff,  
Eliot; Nakano, Hiroyasu; Ware, Carl F. (1)  
CS (1) Biomed. Sci., Univ. Calif., Riverside, CA USA  
SO European Cytokine Network, (1996) Vol. 7, No. 2, pp. 207.  
Meeting Info: 6th International Tumor Necrosis Factor Congress Rhodes,  
Greece May 8-12, 1996  
ISSN: 1148-5493.  
DT Conference  
LA English

=> d his  
(FILE 'HOME' ENTERED AT 12:32:53 ON 11 FEB 2003)  
FILE 'MEDLINE, CANCERLIT, BIOSIS, CONSCIT, EMBASE, CAPLUS, USPATFULL'  
ENTERED AT 12:33:20 ON 11 FEB 2003  
L1 136 S LYMPHOTOXIN (A) BETA (A) RECEPTOR AND ANTIBODY  
L2 42 S L1 AND INTERFERON  
L3 34 DUP REM L2 (8 DUPLICATES REMOVED)  
L4 541 S LYMPHOTOXIN (A) BETA (A) RECEPTOR  
L5 66 S L4 AND PROMOT?  
L6 43 DUP REM L5 (23 DUPLICATES REMOVED)  
L7 48 S L4 AND CANCER  
L8 39 DUP REM L7 (9 DUPLICATES REMOVED)

=> b Browning/in  
'IN' IS NOT A VALID FIELD CODE  
'IN' IS NOT A VALID FIELD CODE  
'IN' IS NOT A VALID FIELD CODE  
'IN' IS NOT A VALID FIELD CODE  
'IN' IS NOT A VALID FIELD CODE  
L9 0 BROWNING/IN

=> s Browning in  
L10 18038 BROWNING IN  
L11 13 L10 AND L4

=> dup rem 111  
PROCESSING COMPLETED FOR L11  
L12 13 DUP REM L11 (0 DUPLICATES REMOVED)  
=> d 1-13

L12 ANSWER 1 OF 13 USPATFULL  
AN 2002:34331 USPATFULL  
TI Soluble lymphotoxin beta receptor and  
anti-lymphotoxin receptor and ligand antibodies as therapeutic agents  
for treatment  
AU Browning, Jeffrey L., Brookline, MA, UNITED STATES  
Hochman, Paula S., Newton, MA, UNITED STATES  
Rembert, Paul D., Millis, MA, UNITED STATES  
Mackay, Fabienne, Vauluse, AUSTRALIA  
PI US 2002197254 A1 20021226  
AI US 2001-3211 A1 20011031 (10)  
RLI Continuation of Ser. No. US 1999-299139, filed on 23 Apr 1999, PENDING  
PRAI WO 1997-US19436 19971024  
US 1996-29060P 19961025 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2115  
INCL INCLM: 424/143.100  
INCL INCLM: 514/012.000  
NCL INCLM: 424/143.100  
NCLM: 514/012.000  
IC [7]  
ICM: A61K039-395  
ICS: A61K038-17  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 13 USPATFULL  
AN 2002:272468 USPATFULL  
TI Tumor necrosis factor receptors galpha & gbeta  
AU Gentz, Reiner L., Rockville, MD, UNITED STATES  
Ebner, Reinhard, Galtersburg, MD, UNITED STATES  
Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES  
Feng, Ping, Galtersburg, MD, UNITED STATES  
Human Genome Sciences, Inc., Rockville, MD, UNITED STATES  
PA corporation)  
PI US 2002150583 A1 20021017  
AI US 2001-895727 A1 20010824 (9)  
RLI Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998,  
PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar  
2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13  
Jan 1998, PENDING  
PRAI US 2001-303224P 20010706 (60)  
US 2000-252313P 20001121 (60)  
US 2000-227598P 20000825 (60)  
US 1999-168235P 19991201 (60)  
US 1999-146371P 19990802 (60)  
US 1999-131964P 19990430 (60)  
US 1998-131270P 19990427 (60)  
US 1998-124092P 19990312 (60)  
US 1998-121774P 19990304 (60)  
US 1997-35496P 19970114 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 12989  
INCL INCLM: 424/178.100  
INCL INCLM: 530/389.100

NCL NCLM: 424/178.100  
NCLS: 530/389.100  
[7]  
ICM: A61K039-395  
ICS: C07H021-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 13 USPTFULL  
AN 2002:171619 USPTFULL  
TI Anti-Lymphotoxin-beta receptor antibodies  
IN as anti-tumor agents  
Browning, Jeffrey L., Brookline, MA, UNITED STATES  
Meier, Werner, Burlington, MA, UNITED STATES  
Benjamin, Christopher D., Beverly, MA, UNITED STATES  
PI US 2002090386 A1 20020711  
AI US 2001-931402 A1 20010816 (9)  
RLI Division of Ser. No. US 1998-875560, filed on 5 Jun 1998, PATENTED A 371 of International Ser. No. WO 1996-US1386, filed on 26 Jan 1996, UNKNOWN Continuation-in-part of Ser. No. US 1995-378968, filed on 26 Jan 1995, PENDING

DT Utility  
FS APPLICATION  
LN CNT 1764  
INCL INCLM: 424/094.100  
INCLS: 424/178.100  
NCL NCLM: 424/094.100  
NCLS: 424/178.100  
[7]  
IC ICM: A61K039-395  
ICS: A61K039-40  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 13 USPTFULL  
AN 2002:157048 USPTFULL  
TI APOPTOSIS INDUCING MOLECULE II AND METHODS OF USE  
IN EBNER, REINHARD, GAITHERSBURG, MD, UNITED STATES  
YU, GUO-LIANG, BERKELEY, CA, UNITED STATES  
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES  
ZHANG, JUN, BETHESDA, MD, UNITED STATES  
ULIRICH, STEPHEN, ROCKVILLE, MD, UNITED STATES  
ZHAI, YIFAN, GAITHERSBURG, MD, UNITED STATES  
PA Human Genome Sciences (U.S. corporation)  
PI US 2002081647 A1 20020627  
US 6495520 B2 20021217  
AI 19990319 (9)  
RLI Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998, PENDING Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-822953, filed on 21 Mar 1997, ABANDONED

PRAI US 1998-75409P 19980220 (60)  
US 1996-13923P 19960322 (60)  
US 1996-30157P 19961031 (60)

DT Utility  
FS APPLICATION  
LN CNT 6195  
INCL INCLM: 435/069.100  
INCLS: 530/350.000; 530/399.000; 514/012.000; 536/023.500  
NCL NCLM: 514/012.000  
NCLS: 530/300.000; 530/324.000; 530/350.000  
[7]  
IC ICM: A61K038-18  
ICS: C12P021-06; C07H021-04; C07K014-00; G01N033-53  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 13 USPTFULL

AN 2002:126357 USPTFULL  
TI APOPTOSIS INDUCING MOLECULE II  
IN EBNER, REINHARD, GAITHERSBURG, MD, UNITED STATES  
YU, GUO-LIANG, DARNESTOWN, MD, UNITED STATES  
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES  
ULIRICH, STEPHEN, ROCKVILLE, MD, UNITED STATES  
PA Human Genome Sciences, Inc. (U.S. corporation)  
PI US 2002064869 A1 20020530  
US 6479254 B2 20021112  
AI US 1998-27287 A1 19980220 (9)  
RLI Continuation-in-part of Ser. No. US 1997-822953, filed on 21 Mar 1997, ABANDONED

PRAI US 1996-30157P 19961031 (60)  
US 1996-13923P 19960322 (60)

DT Utility  
FS APPLICATION  
LN CNT 4242  
INCL INCLM: 435/320.100  
INCLS: 435/069.100; 435/325.000; 536/023.500  
NCL NCLM: 435/069.100  
NCLS: 435/069.700; 435/320.100; 435/325.000; 530/324.000; 536/023.400; 536/023.500; 536/024.100; 930/144.000  
[7]  
IC ICM: C12N015-63  
ICS: C07H021-04; C12N015-00; C12N015-74; C12N005-06; C12N015-70; C12N015-09  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 6 OF 13 USPTFULL  
AN 2002:72443 USPTFULL  
TI Method for the high level expression of active Lymphotoxin-beta receptor immunoglobulin chimeric proteins and their purification  
IN Browning, Jeffrey, Brookline, MA, UNITED STATES  
Mlakowski, Konrad, North Reading, MA, UNITED STATES  
Meier, Werner, Burlington, MA, UNITED STATES  
PI US 2002039580 A1 20020404  
AI US 2001-767370 A1 20010123 (9)  
RLI Continuation of Ser. No. WO 1999-US29873, filed on 16 Dec 1999, UNKNOWN

PRAI US 1998-112752P 19981217 (60)

DT Utility  
FS APPLICATION  
LN CNT 1163  
INCL INCLM: 424/178.100  
INCLS: 530/389.100; 435/069.700; 435/328.000; 530/351.000  
NCL NCLM: 424/178.100  
NCLS: 530/389.100; 435/069.700; 435/328.000; 530/351.000  
[7]  
IC ICM: A61K039-395  
ICS: C12P021-04; C07K016-46  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 7 OF 13 USPTFULL  
AN 2002:26858 USPTFULL  
TI Antagonists of tweak and of tweak receptor and their use to treat immunological disorders  
IN Remmett, Paul, Mills, MA, UNITED STATES  
PI US 2002015703 A1 20020207  
AI US 2001-905810 A1 20010713 (9)  
WO 2000-US1044 20000014  
PRAI US 1999-116168P 19990115 (60)

DT Utility  
FS APPLICATION  
LN CNT 1303  
INCL INCLM: 424/143.100

NCL NCLM: 424/143.100  
 IC [7]  
 ICM: A61K039-395  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 8 OF 13 USPTAFULL  
 AN 2002:8587 USPTAFULL  
 TI Multivalent antibodies and uses thereof  
 IN Miller, Kathy L., San Francisco, CA, UNITED STATES  
 PRAI Presta, Leonard G., San Francisco, CA, UNITED STATES  
 PI GENENTECH, INC. (U.S. corporation)  
 AI US 2002004587 AI 20020110  
 AI US 2001-813341 AI 20010320 (9)  
 PRAI US 2000-195819P 20000411 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 4913  
 INCL INCLM: 530/388.800  
 INCLM: 536/023.500; 435/325.000; 435/334.000; 424/143.100  
 NCL NCLM: 530/388.800  
 NCLM: 536/023.500; 435/325.000; 435/334.000; 424/143.100  
 IC [7]  
 ICM: C07K036-28  
 ICS: A61K039-395; C07H021-04; C12N005-06  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 13 USPTAFULL  
 AN 2002:3612 USPTAFULL  
 TI Reversal of viral-induced systemic shock and respiratory distress by  
 IN blockade of the lymphotoxin beta pathway  
 Browning, Jeffrey, Brookline, MA, UNITED STATES  
 PRAI Pugliese, Maryann, Alexandria, VA, UNITED STATES  
 PI Ahmed, Rafi, Atlanta, GA, UNITED STATES  
 AI US 2002001585 AI 20020103  
 AI US 2001-823031 AI 20010409 (9)  
 RLI Continuation of Ser. No. WO 1999-0523477, filed on 8 Oct 1999, UNKNOWN  
 PRAI US 1998-10362P 19981009 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1040  
 INCL INCLM: 424/143.100  
 INCLM: 424/147.100; 435/328.000; 435/334.000  
 NCL INCLM: 424/143.100  
 NCLM: 424/147.100; 435/328.000; 435/334.000  
 IC [7]  
 ICM: A61K039-42  
 ICS: A61K039-395; C12N005-06; C12N005-16  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 10 OF 13 USPTAFULL  
 AN 2002:136562 USPTAFULL  
 TI Soluble lymphotoxin-.beta. receptors as  
 IN therapeutic agents for the treatment of immunological disease  
 Browning, Jeffrey L., Brookline, MA, United States  
 PRAI Benjamin, Christopher D., Beverly, MA, United States  
 PI Hochman, Paula S., Newton, MA, United States  
 AI Biogen, Inc., Cambridge, MA, United States (U.S. corporation)  
 US 6403087 BI 20020611  
 WO 9703687 19970206  
 US 1998-166 19980608 (9)  
 WO 1996-US12010 19960719  
 RLI Continuation-in-part of Ser. No. 1995-505606, filed on 21 Jul 1995,  
 DT Utility  
 Utility now patented, Pat. No. US 5923351

FS GRANTED  
 LN.CNT 1983  
 INCL INCLM: 424/134.100  
 INCLM: 424/133.100; 514/002.000; 514/008.000; 530/387.100;  
 INCLM: 424/134.100  
 NCL NCLM: 424/134.100  
 NCLM: 530/387.100  
 IC [7]  
 ICM: A61K039-395  
 ICS: A61K038-16  
 EXF 424/148.1; 424/144.1; 424/145.1; 424/156.1; 514/2; 514/8; 530/395;  
 530/387.1; 530/388.22; 530/388.23; 530/388.73; 530/388.85; 530/389.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 11 OF 13 USPTAFULL  
 AN 2001:196600 USPTAFULL  
 TI Lymphotoxin-.alpha.-.beta. complexes and anti-lymphotoxin-.beta. receptor  
 IN antibodies as anti-tumor agents  
 Browning, Jeffrey L., 32 Milton Rd., Brookline, MA, United States 02146  
 PRAI Meier, Werner, 31 Bedford St., Burlington, MA, United States 01803  
 PI Benjamin, Christopher D., 2 Oak Hill La., Beverly, MA, United States  
 01915  
 AI US 6312691 BI 20011106  
 WO 9622788 19960801  
 AI US 1998-875560 19980605 (8)  
 WO 1996-US1386 19960126  
 19980605 PCT 102(e) date

DT Utility  
 FS GRANTED  
 LN.CNT 2254  
 INCL INCLM: 424/143.100  
 INCLM: 424/130.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;  
 INCLM: 424/130.100; 530/388.750; 530/388.800; 530/388.850  
 NCL NCLM: 424/143.100  
 NCLM: 424/130.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;  
 IC [7]  
 ICM: A61K039-395  
 EXF 424/130.1; 424/143.1; 424/144.1; 424/809; 530/388.22; 530/388.7;  
 530/388.75; 530/388.8; 530/388.85  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 12 OF 13 USPTAFULL  
 AN 2000:146513 USPTAFULL  
 TI Lysand for herpes simplex virus entry mediator and methods of use  
 IN Ware, Carl E., Solana Beach, CA, United States  
 PRAI La Jolla Institute for Allergy and Immunology, La Jolla, CA, United  
 States (U.S. corporation)  
 PI US 6140467 20001031  
 AI US 1997-898234 19970730 (8)  
 PRAI US 1997-51964P 19970707 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 1522  
 INCL INCLM: 530/350.000  
 INCLM: 530/350.000  
 NCL NCLM: 530/350.000  
 IC [7]  
 ICM: C07K014-47  
 EXF 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 13 OF 13 USPTAFULL  
 AN 1999:81543 USPTAFULL  
 TI Soluble lymphotoxin-.beta. receptors and

anti-lymphotoxin receptor and ligand antibodies as therapeutic agents  
for the treatment of immunological disease  
IN Browning, Jeffrey L., Brookline, MA, United States  
Benjamin, Christopher D., Beverly, MA, United States  
Hochman, Paula S., Brookline, MA, United States  
PA Biogen, Inc., Cambridge, MA, United States (U.S. corporation)  
FI US 5925351 19990720  
AI US 1995-505606 19950721 (8)  
DT Utility  
FS Granted  
LN.CVT 1968  
INCL INCLM: 424/143.100  
INCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000;  
530/395.000; 530/387.100; 530/388.220; 530/388.230; 530/388.730;  
530/388.850; 530/389.200  
NCL NCLM: 424/143.100  
NCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000;  
530/387.100; 530/388.220; 530/388.230; 530/388.730; 530/388.850;  
530/389.200; 530/395.000  
IC [6]  
ICM: A61K039-395  
ICS: A61K038-16; C07K015-00; C07K016-28  
EXP 514/218; 530/395; 530/387.1; 530/388.22; 530/388.23; 530/388.73;  
530/388.85; 530/389.2; 424/143.1; 424/144.1; 424/145.1; 424/156.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>  
--Logging off of STN--

=>  
Executing the logoff script...

=> LOG Y  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
168.21 168.42  
STN INTERNATIONAL LOGOFF AT 12:55:25 ON 11 FEB 2003